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  Age is the single greatest factor associated with increased risk for prostate 
cancer development. Evidence implicates progressive age-related immune dysfunction 
with increased prostate cancer incidence. The aged T cell response is characterized by 
increased production of pro-inflammatory cytokines, which could significantly 
contribute to prostate tumorigenesis through induction of key pro-survival factors.  The 
objective of these studies was to determine how age-related changes in T-lymphocyte 
function contribute to prostate tumorigenesis. The hypothesis that age-related changes 
in T-lymphocyte function to a pro-inflammatory phenotype promote prostate cancer 
development was tested using the glycerol-3-phosphate acyltransferase-1 (GPAT-1) 
knock-out mouse, which mimics many of the characteristics of an aged immune system.  
T cells from old (24-month) mice and aging-mimic T cell GPAT-1-/- mice generate more 
pro-inflammatory cytokines than T-lymphocytes from wild type mice. These cytokines 
turn on inflammatory pathways that stimulate proliferation, tissue disruption, and 
tumor growth. Initial studies showed that secreted factors from aging and T cell aging-
 vii 
mimic GPAT-1-/- mice produce circulating factors that induce pro-inflammatory 
pathways in prostate cells, most notably the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB). Additionally, results from recent experiments demonstrate 
that serum from the GPAT-1 -/- mice induce protein expression of downstream targets of 
NF-κB in the prostate, most notably factors that induce macrophage infiltration and key 
pro-survival proteins. Furthermore, my experimental results suggest that the increased 
production of interleukin 17 (IL-17) by aged T cells play a role in the induction of pro-
inflammatory pathways in the prostate. Based on these findings additional studies were 
design to determine if the increased production of pro-inflammatory cytokines by aging 
T-lymphocytes contributes to a more malignant phenotype in the prostate. Finally, the 
inter-relationship between an aging immune system and the aging tissues in the body 
was explored. Findings from these studies provide evidence that the dysregulation of 
cytokine production seen in aged T cells may directly contribute to the increased risk for 
prostate cancer in the elderly. This new perspective regarding the role of the aging 
immune system in cancer development opens new avenues for development of 
potential preventive interventions and screening biomarkers. 
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Chapter 1:  Introduction 
1.2 Aging, Immunity, and Prostate Cancer Risk 
Prostate cancer risk is strongly age dependent, rarely appearing before age  40  
and typically affecting men around 70 years of age [1]. This association with age 
suggests that prostate cancer results from accumulation of genetic damage, perhaps 
due to oxidative stress or other endogenous or exogenous factors. During aging, there is 
a progressive accumulation of DNA damage and oxidative stress in most tissues, and this 
plays an important role in age-related tumorigenesis [2, 3]. In addition, there are 
significant changes in immune response regulation that accompany the aging process. 
These include increased pro-inflammatory cytokine production, as well as a decrease in 
appropriate immune surveillance. The importance of the immune system in preventing 
tumorigenesis has been supported by numerous research studies as well as 
epidemiological evidence [4]. Aging has multiple effects on the development, function 
and turnover of immune cells. In fact, aging is associated with low number of naïve T 
cells, decreased diversity and functionality of CD4+ and CD8+ T cells and inability to 
respond appropriately to antigens [5, 6]. Additionally, aging is associated with a low-
grade chronic inflammation. Inflammation is critical for fighting infections in the elderly; 
a chronic low-grade inflammation is deleterious and highly correlated with prostate 
cancer risk [7, 8].  
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The retention of inflammatory responses in the elderly accompanied with the 
absence of counterbalancing and beneficial effects highly enhance the likelihood of 
developing prostate cancer.  
1.2 Inflammation and Prostate Carcinogenesis 
Chronic inflammation is believed to play a pathogenic role in age-related 
diseases, including prostate cancer. The role of inflammation in prostate cancer 
tumorigenesis has been well established.  Most lesions that contain inflammatory 
infiltrates are associated with prostatic atrophy [7, 9].  
Additionally, several key molecular pathways involved in prostate carcinogenesis 
have been associated with chronic or acute prostatic inflammation. Pro-inflammatory 
cytokines activate key transcription factors such as, nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB ) or signal transducer and activator of transcription 
3 (STAT3), in prostate epithelial cells. NF-κB and STAT3 control numerous pro-
tumorigenic process, including survival, proliferation, growth, angiogenesis, and 
invasion.  As part of a positive feedback loop, NF-κB and STAT3 induce production of 
additional chemokines that attract inflammatory cells to the prostate and help sustain 
an inflammatory environment [10].  
Prostatic tissue normally contains endogenous immune cells, including T and B 
lymphocytes and macrophages. However, aging prostate tissue contains increased 
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inflammatory infiltrates. Aging prostate tissue has an increased number of macrophages 
and leukocytes. Studies by Steiner et al. demonstrated that most T cell in older prostate 
tissue expressed CD4+ T cells; however non-inflamed younger prostate tissues expressed 
mostly CD8+ T cells [11, 12]. Furthermore, Steiner et al. showed that activated T cells in 
chronically inflamed prostate tissue express high levels of IL-17 [13]. These diverse 
inflammatory infiltrates in the prostate communicate with each other by means of 
direct contact and cytokine production, and control prostate tumor initiation and 
promotion 
Inflammation can contribute to prostate tumor initiation through increase in 
mutation rates, genomic instability and epigenetic modifications. Inflammation 
enhances the production of growth factors and cytokines that enhance the proliferation 
of mutated cells. Additionally, p53 mutations, caused by oxidative damage, were found 
in both cancer cells and inflamed epithelium, suggesting that chronic inflammation 
causes genomic mutations [14, 15]. Other findings, implicate that inflammation 
influences epigenetic mechanisms, including microRNA-based silencing and DNA 
methylation. One study demonstrated that inflammation plays a role in epigenetic 
reprogramming through regulation Jmjd3 which is encoded by a NF-kB target gene [16]. 
The connection between inflammations and prostate tumor initiation is not a one way 
street, studies have shown that DNA damage can lead to inflammation and thereby 
promote prostate tumorigenesis [16]. 
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Aged related inflammation can affect every aspect of prostate tumor 
development and progression, via multiple mechanisms. Controlling inflammatory 
status may allow successful prevention and control of prostate tumorigenesis. 
1.3 Mouse Model of Aging T-lymphocytes 
1.3.1 The Mouse as a Model Organism in Human Aging Research 
Aging is commonly defined as the accumulation of diverse deleterious changes 
occurring in cells and tissues. Aging is characterized by decrease in physiological 
capacity, reduced ability to respond adaptively to environmental stimuli and increased 
vulnerability to disease [17].  
Using humans as subjects in aging research is complicated due to ethical issues, 
long life span, environmental influences, and various other limiting factors. Therefore, 
various animal models have been developed to study the biology of aging [17, 18]. 
Animal models used to investigate the human biology of aging and age-related diseases 
should mimic the biological changes that occur in humans while controlling for genetic 
background, diet, environmental changes and health status. Non-mammalian models, 
such as worms and fruit flies, have some advantages and have been useful in the study 
of aging-related genes. However, in order to understand the complexity of aging in 
humans, mammalian model organisms are indispensable. Primates should be ideal in 
that respect, but ethical issues and long life span make studies with primates 
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complicated. On the contrary, mice are good models for studying human aging. Not only 
can they be genetically modified but longitudinal studies are easy to conduct on mice 
because of their short life span [18]. 
1.3.2 Current Mice Models for Aging Research 
Animal models use to study accelerated aging, aging biology and aging related 
diseases are generally grouped into four classes: experimentally induced models, gene-
modified models, selection models, and spontaneous models. Researchers interested in 
the mechanisms of normal aging have to be prudent in their choice of animal models 
because early diseases leading to reduced life spans usually result from certain defects 
unrelated to mechanisms associated with normal aging. It can be difficult to distinguish 
between accelerated aging due to acceleration of the normal aging process and 
accelerated aging due to the manifestation of pathologies.  
One model that has been used to study accelerated aging is the thymectomized 
lab mouse. When male mice are thymectomized their mean life span is reduced [19]. 
The reduced life span is thought to be due to accelerated aging of the immune system 
that involves a decline in spleen cell responsiveness to T cell mitogens [20]. Thymectomy 
reduces the number of peripheral CD4+ T cells and affects the CD4+ T cell population by 
changing it to a memory phenotype and removing their self-renewability. The 
thymectomized mice model can be useful for studying the effects of age related decline 
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in thymus function. The function of the thymus is known to decline in adults.  In the 
elderly the thymus is barely identifiable, consisting mostly of fatty tissue [19, 21]. The 
thymectomized model of accelerated aging presents some limitations. First of all, the 
complete lack of a functional thymus is not representative of actual aging. Because 
despite the thymus involution that comes with age, the thymus continues its endocrine 
function. Additionally, Smolarchuk et al. found that thymectomized lab mice could 
generate T cells without contribution from the thoracic thymus. However, these mice 
had increased proportions of effector memory T cells and Regulatory T cells (Treg) 
phenotype cells, increased serum IgG1/2b, and increased frequency of  T cells 
expressing IFN-γ, IL-17 or IL-10 [22]. Other studies have demonstrated that mice that 
received a thoracic thymectomy developed autoimmune gastritis [23]. Together the 
data from thymectomized lab mice suggests that this is not the best model for aging 
research.  
Other mouse models for aging research are the klotho mouse model and the 
Senescence-accelerated mouse model (SAM). The klotho mouse model was generated 
by inserting a mutated transgene that disrupt the klotho gene locus. Klotho mice display 
various phenotypes resembling premature aging. Mice homozygous for the transgene 
show arteriosclerosis, osteoporosis, age-related skin changes, short lifespan and 
infertility, and growth retardation. The klotho gene encodes a membrane protein that 
shares a sequence similarity with the β-glucosidase enzymes and is expressed mainly in 
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the kidney and the brain.  The klotho mice model is useful to study molecular-genetic 
mechanisms of both premature aging and accelerated aging. However, some common 
phenotypes seen in natural human aging are not present in klotho mice [24]. 
Additionally, klotho mice develop dramatic physiological changes that are not present in 
normal aging. Therefore, klotho mice are better suited as model for human progeroid 
syndrome rather than normal human aging. 
The senescence-accelerated mouse (SAM) consists of fourteen senescence-
prone inbred strains (SAMP) and four senescence-resistant inbred strains (SAMR). The 
manifestation of senescence in SAMP does not occur in the developmental stage, but it 
occurs in an accelerated manner following normal development, though there is no 
evidence of growth retardation, malformation, limb palsy, or other neurological signs, 
such as tremors and convulsions. The life span of SAMP is about 40 percent shorter than 
that of SAMR. Thus, accelerated senescence is considered to be a characteristic feature 
common to all SAMP mice. Both SAMP and SAMR strains manifest various aging related 
phenotypes, which are often characteristic enough to differentiate the strains. These 
phenotypes include impaired immune response, hyperinflation of the lungs, hearing 
impairment, deficits in learning and memory, cataracts, alveolar bone loss, degenerative 
joint disease, abnormality of circadian rhythms, emotional disorders, and brain atrophy 
[25, 26].  
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Senescence-accelerated mice (SAM) and their substrains have been developed 
for the study of human aging and are known to exhibit aging phenotypes. The pitfall of 
SAM mice as model for aging research is that the different aging phenotypes associated 
with SAM are distributed among the various SAM substrains and multiple gene 
mutations are implicated in causing the phenotypes observed in the SAM mouse model 
[24]. 
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1.3.3 The glycerol-3-phosphate acyltransferase-1 (GPAT-1) knock-out mouse of T-
lymphocyte aging 
 Glycerol-3-phosphotate acetyltransferases are rate limiting enzymes of 
triacylglycerol biosynthesis.  There are four homologous isoforms of glycerol-3-
phosphate acyltransferase (GPAT), each the product of a separate gene that catalyzes 
the synthesis of lysophosphatidic acid from glycerol-3-phosphate and long-chain acyl-
CoA. GPAT-1 and 2 are found in the mitochondria and GPAT-3 and 4 are found in the 
micirosome [27]. GPAT-1 influences biological membrane composition which can have a 
profound effect on T cell function. While other tissues express both GPAT-1 and GPAT-2 
on the mitochondria membrane, GPAT-1 is the only mitochondrial isoform expressed in 
T-lymphocytes [28].  
The GPAT-1 knock-out mouse provides an unprecedented opportunity to 
investigate the effects of an aging T-lymphocyte population in the absence of other age 
related complications. Since GPAT-1 is the only mitochondrial isoform expressed in T-
lymphocytes, GPAT-1 -/- mice display only minimal phenotype in other tissues.  GPAT-1 
catalytic activity is significantly down-regulated in aged rat-liver and T-lymphocytes, 
suggesting that impairment of the GPAT-1 mediated lipid biosynthetic pathway is a 
physiologically relevant event in the natural course of aging [29].  
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GPAT-1-/- mice T-lymphocytes possess multiple hallmarks of aging.  Without 
GPAT-1, T cell proliferation is inhibited and activation induced apoptosis is increased. 
Importantly, consistent with an immune-senescent phenotype, TH1 cytokine secretion is 
reduce in stimulated splenic T cells form GPAT-1-/- mice [30]. Additionally, T-lymphocytes 
from the GPAT-1-/- mouse up-regulate the production and secretion of pro-inflammatory 
cytokines [30, 31].  
The GPAT-1-/- is the only animal model to mimic the membrane lipid and 
functional phenotype changes of an aged T cell with no other pathological conditions. 
Investigations on how specific aspects of the aging process contribute to prostate 
tumorigenesis are extremely difficult due to the multiple morbidities associated with 
aging. The GPAT-1 -/- mouse model provides an opportunity to investigate how T cell 
aging contributes to prostate cancer development. 
1.4 Aging T-lymphocytes, Interlukin-17 and Prostate Tumorigenesis 
It has been widely accepted that aging is characterized by a pro-inflammatory 
imbalance of TH1/TH2 cells [6].  A third subset of T helper cells, TH17, has been 
implicated in the development of chronic inflammation in the elderly.  Schmitt et al. 
demonstrated that, on a basal resting level, TH17 cells were at a significantly increased 
level in older individuals. Other groups have also demonstrated that the proportion of 
TH17 cells was garter in aged mice both in naïve and memory cell populations [32]. Some 
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investigators suggest that elevation of IL-1β and IL6 and reduction of IL-2 expression in 
aged mice promote TH17 differentiation [33, 34].  
TH17 cells are characterized by producing pro-inflammatory cytokines IL-17, IL-21 
and IL-22. IL-17 is a pro-inflammatory cytokine that is involved in recruiting 
inflammatory cells and induction of pro-inflammatory mediators [35]. As a pro-
inflammatory cytokine, IL-17 has been implicated in a number of diseases including 
rheumatoid arthritis, asthmatic airways, allergic skin immune responses and the 
inflammatory process associated with strokes [36]. Additionally, IL-17 is produce by 
tumor infiltrating lymphocytes, and increases tumorigenicity in a number of cancers. IL-
17 has also been implicated in tumor vascularization of cervix and ovarian cancer [13]. 
IL-17 exerts its effects through a family of receptors comprised of five members (IL17-
RA, RB, RC, RD and RE). The roles of IL-17RD and IL-17RE are not clear, while IL-17B, 
IL17C and IL-17D are currently poorly studied with regards to their biological functions 
and receptors. IL-17RA forms a receptor heterodimer with IL-17RC. The receptor 
heterodimer is the preferred form by IL-17 ligands. When IL-17 binds to IL-17RA/C it 
activates NF-κB and MAPK signaling pathways [37] . 
 The contribution of IL-17 to prostate cancer has been reported by various 
investigators [11, 13, 38-45]. Isoforms of the IL-17 receptor have been detecte in certain 
prostate cancers [44].  Moreover, IL-17A expression is increase in 58% of prostate 
cancer biopsies and IL-17RA and IL-17RC receptors are expressed in aggressive forms of 
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prostate cancer [13]. It has also been reported that TH17 cell number is increased in 
prostate cancer [45] and a higher percentage of TH17 in the blood is correlated with a 
poorer outcome [38]. Recently, Zhang et al. also reported that IL-17 promotes the 
formation and growth of prostate adenocarcinoma in a mouse model of autochthonous 
prostate cancer and that IL-17 promotes development of castration resistant prostate 
cancer [42, 43]. Taken together the current knowledge indicates that there is a potential 
link between increased IL-17 expression in the elderly and prostate cancer development 
and progression. 
1.5 Aging, Interlukin-6 and Prostate Tumorigenesis. 
 IL-6 is the most prominent cytokine that is shared across age-related 
pathologies having a strong chronic inflammatory component. There is strong evidence 
that IL-6 serum concentration increases with age [46-49].  Maggio et al. reported that IL-
6 mean values ranged from 1.4 pg/ml (men) and 1.1 pg/ml (women) in the 65–74 years 
age group to 3.5 pg/ml (men) and 2.1 pg/ml (women) in persons 85 years and older, and 
that the age trend is partially independent of major confounders [48]. Age-related 
increments in IL-6 are not explained by differential prevalence of IL-6 gene 
polymorphisms [50]. The etiology of chronically elevated IL-6 in older adults is likely 
multifactorial, with increased presence of disease states, declines in estrogen and 
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testosterone levels and changes in the immune system function and regulation all 
contributing to increases in IL-6 levels. 
 IL-6 expression is mainly modulated by the nuclear NF-κB. A number of different 
stimuli, including cytokines, infections, and toxins, induce IL-6 expression. The binding of 
IL-6 to its receptor activates two distinct signaling pathways: The Janus tyrosine family 
kinase (JAK)-signal transducer and activator of transcription (STAT) pathway and the 
extracellular signal-regulated kinase 1 and 2 (ERK1/2)-mitogen activated protein kinase 
(MAPK) pathway [51, 52]. The physiological role of IL-6 is to initiate and coordinate 
acute phase response, but there is strong evidence indicating that IL-6 also plays a 
central role in the pathogenesis of chronic disease.  
In cancer, IL-6 is a growth/survival factor for a variety of tumor types. In prostate 
cancer, activation of STAT3 by IL-6 is correlated with increase proliferation, decreased 
apoptotic potential, regulation of epithelial-mesenchymal transition (EMT) and 
activation of androgen receptor genes [53].  An extensive literature suggests that IL-6 
plays a critical role in prostate cancer initiation and progression [15, 39, 41, 53-57].  
Overall, the retention of strong inflammatory responses accompanied with the 
absence of counterbalancing and beneficial effects of the immune system highly 
enhance the likelihood of developing prostate cancer in the elderly. A better 
understanding of the regulation and role of IL-6 and IL-17 in aging-related prostate 
cancer is required to develop effective therapeutic and prevention treatments. 
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1.6 Dissertation Objectives      
  Epidemiological studies suggest that after 50 years of age, men experience a 
progressively heightened risk of being diagnosed with prostate cancer with each 
subsequent year of life. This is due to several factors, including an increased duration of 
carcinogenesis, accumulation of DNA damage and an increased susceptibility of aging 
cells to environmental carcinogens. Another important mechanistic link between aging 
and prostate cancer is reduced immune function. As the immune system is strongly 
implicated in modulating systemic inflammation, and because the phenotypic 
functionality of immune-regulatory cells changes with age, immune dysfunction may 
actively promote prostate carcinogenesis in the elderly.  
The objective of these studies was to determine how age-related changes in T-
lymphocyte function contribute to prostate tumorigenesis. We hypothesized that age 
related changes in T-lymphocyte function, towards a pro-inflammatory phenotype may 
promote prostate cancer development. The rationale behind our hypothesis was largely 
based on preliminary data suggesting that, consistent with an aged phenotype, T-
lymphocytes from the GPAT-1-/- mouse up-regulate the production and secretion of pro-
inflammatory cytokines. Many of the pro-inflammatory cytokines produced by aged T-
lymphocytes have been implicated in the promotion of prostate tumorigenesis, 
primarily through the induction of other pro-inflammatory pathways and the activation 
of transcription factors like NF-κB. 
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Given that preliminary data indicated that T-lymphocytes from aging mimic 
GPAT-1 -/- mice secrete high levels of IL-17, a key cytokine known to promote 
carcinogenesis, and that transcription factors like NF-κB are critical for both 
inflammation and tumor growth, we tested the role of IL-17 in GPAT-1-/--induced NF-κB 
activity.  
After we had established that the aged T-cell response is in part characterized by 
increased production of cytokines that induce pro-inflammatory pathways in prostate 
cells, the next objective of my study was to determine if the increased production of 
pro-inflammatory cytokines by aging T-lymphocytes contributes to a more malignant 
phenotype in the prostate.  
Given the prominent role of IL-6 in age-related pathologies with a chronic 
inflammatory component, it was also important to further understand the role of 
circulating levels of IL-6 in age-related prostate tumorigenesis.  
This study is one of the first to explore the relationship between aging T-
lymphocytes and prostate tumorigenesis. The research presented in this dissertation is 
highly relevant because the potential identification of pathways and biomarkers could 
help develop effective treatments for prostate cancer. 
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Chapter 2:  Age-related Alterations in T-lymphocytes Modulate Key Pathways in 
Prostate Tumorigenesis 
2.1 Introduction  
Age is the single greatest factor associated with increased risk for prostate 
cancer development [1].  Epidemiological studies suggest that after the fifth decade of 
life, men experience a progressively heightened risk of being diagnosed with prostate 
cancer with each subsequent year of life until the age of 85 [58]. While localized events 
within the tissue microenvironment over time may influence prostate carcinogenesis, 
the contribution that cytokines impart on tumor initiation and development has been 
underexplored. As the immune system is strongly implicated in modulating systemic 
inflammation, and because the repertoire and phenotypic functionality of immune-
regulatory cells changes with age, immune dysfunction may actively promote prostate 
carcinogenesis. To date, the limitation in delineating the precise contribution of aged 
immune cells to prostate cancer initiation has been a lack of appropriate models that 
recapitulate normal aging [30].  
Recently we have developed a novel mouse model of accelerated T-lymphocyte 
aging, the glycerol-3-phosphate acyltransferase-1 (GPAT-1) knock-out mouse, in which 
young T lymphocytes possess multiple hallmarks of aging [28, 29, 59]. The GPAT-1 
knock-out mouse provides an unprecedented opportunity to investigate the effects of  
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an aging T-lymphocyte population on prostate cancer development in the 
absence of other age related complications.  GPAT-1 is an integral mitochondrial outer 
membrane protein that initiates the first and rate limiting step in de novo phospholipid 
and triacylglycerol biosynthesis [30].  GPAT-1 is one of four known isoforms (two on the 
mitochondria and two on the endoplasmic reticulum) and is the only mitochondrial 
isoform expressed in T-lymphocytes.  Only a minimal phenotype is found in other 
tissues, which express both GPAT-1 and GPAT-2 on the mitochondrial membrane [28]. 
We have shown that GPAT-1 catalytic activity is significantly down-regulated in aged rat-
liver and T-lymphocytes, suggesting that impairment of the GPAT-1 mediated lipid 
biosynthetic pathway is a physiologically relevant event in the natural course of aging 
[29, 59]. Consistent with an aged phenotype, T-lymphocytes from the GPAT-1-/- mouse 
up-regulate the production and secretion of pro-inflammatory cytokines [30]. Many of 
the pro-inflammatory cytokines produced by aged T-lymphocytes have been implicated 
in the promotion of prostate tumorigenesis, primarily through the induction of other 
pro-inflammatory pathways and by driving the activation of transcription factors such as 
NF-κB.  Analogous engagement of these pathways is recapitulated in GPAT-1-/- T-
lymphocytes, strongly suggesting that the aged immune system plays a critical role in 
promoting prostate carcinogenesis.   
NF-κB, a key mediator of gene transcription during the immune response, 
becomes deregulated during carcinogenesis.  NF-κB-mediated gene transcription drives 
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the expression of key survival factors that suppress apoptosis, promote cellular 
proliferation, and incite the inflammatory response [60]. The current emphasis in cancer 
immunology is to elucidate the biological pathways by which immune cells enhance 
inflammation to promote tumor development and progression.  
We demonstrated that secreted cytokines from GPAT-1-/- T-lymphocytes closely 
mimic the cytokine array profile observed in normal aged T-lymphocytes.  Treatment of 
normal, non-transformed or prostate cancer cells with serum derived from the GPAT-1-/- 
mice induced NF-κB transcriptional activity and nuclear localization.  Aging and aging-
mimic GPAT-1-/- T-lymphocytes secrete factors which, when compared to young wild-
type T-lymphocytes, differentially induce NF-κB activation and promote cellular 
proliferation in prostate epithelial cells.  These data strongly suggest that the aging 
immune system is not a passive component to tumorigenesis, but may actively promote 
initiation and progression through induction of inflammatory pathways. 
2.2   Materials and methods       
2.2.1      Murine Models of an Aging Immune System 
C57BL/6 GPAT-1 +/- mice were obtained from Dr. Rosalind Coleman (University 
of North Carolina at Chapel Hill) and bred in our animal facilities to obtain homozygous 
knock-outs.  Mice were fed a commercial chow diet (Prolab Rat/Mouse/Hamster 2000) 
provided by the animal facility.  Offspring were numbered to monitor sex differences or 
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differences between litters. Aged (+22 months) C57BL/6 mice were purchased from the 
National Institute for Aging. Mice were housed on a 12:12-h light-dark cycle and had 
free access to commercial chow food and water.   
2.2.2 T-lymphocyte isolation and stimulation  
Splenic T-lymphocytes were isolated from young (6 month) wild-type (WT), 
young (6 month) GPAT-1 KO, and old (22 month) WT mice using negative selection 
(Miltenyi magnetic microbeads and antibody T-lymphocyte specific antibody 
combinations) as per the manufacturer's instructions, yielding a 95% pure splenic T-
lymphocyte population.  Isolation by negative selection prevents perturbation of the T-
lymphocyte's receptor during the isolation procedure, as occurs with isolation via 
positive selection-lymphocytes were stimulated at 37°C in pre-warmed complete RPMI 
1640 culture media (10% heat-inactivated fetal bovine serum plus 100 U/ml penicillin, 
100 µg/ml streptomycin, 10 µM 2-mercaptoethanol, and 100 mM L-glutamine) with 
either 10 µg/ml plate-bound anti-CD3 and 1 µg/ml anti-CD28 or no stimulation as we 
have previously described (4). Anti-CD3 and CD28 antibodies are routinely used as 
polyclonal mitogens to mimic the in vivo T-cell response.  After 24 hours of stimulation, 
the T-lymphocyte culture supernatant (conditioned media) was collected and used in 
subsequent experiments.  All animal procedures used were approved by the University 
of Texas Animal Use and Care Committee. 
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2.2.3 Cell Lines 
The LNCaP and PC-3 cell lines were purchased from the American Type Culture 
Collection (Rockville, MD) and grown in RPMI-1640 containing penicillin and 
streptomycin, supplemented with 10% fetal bovine serum (FBS) in a 5% (v/v) CO2 
humidified incubator at 37°C. The immortalized non-transformed RWPE-1 prostate 
epithelial cell line was purchased from American Type Culture Collection and grown in 
Keratinocyte Serum Free Medium (K-SFM) supplemented with bovine pituitary extract 
(BPE) and human recombinant epidermal growth factor (EGF) in a 5% (v/v) CO2 
humidified incubator at 37°C. The PrEC-human normal prostate epithelial cell line was 
purchased from Lonza (Basel, Switzerland) and grown in PrEGM Prostate Epithelial Cell 
Growth Medium containing a growth factor and cytokine-supplemented SingleQuots kit. 
2.2.4 Cytokine Array 
Conditioned media from splenic T-lymphocytes from wild-type young (6 week), 
old (22 months) and young GPAT-1-/- (6 week) mice were obtained by stimulating 
isolated T-cells with either 10 µg/ml plate-bound anti-CD3 and 1 µg/ml anti-CD28 in 
NaHCO3 or 10 nM phorbol myristate acetate (PMA) and 1 µM ionomycin.  The cytokine 
profiles were performed using R&D Systems Mouse Cytokine Array, Panel A (R&D 
Systems Minneapolis, MN, USA) according to the manufacture’s recommendations. 
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2.2.5 Dual Luciferase assay 
LNCaP and RWPE-1 cells seeded in 6-well plates were grown to 60–80% 
confluence for transfection. 1μg NF-kB luciferase reporter plasmid (Stratagene, La Jolla, 
CA) and 20ng of control Renilla reporter plasmid were concurrently transfected together 
using FuGENE 6 (Roche, Valencia, CA, USA) transfection reagent, according to 
manufacturer’s protocol. At 24 hr post-transfection, 10% sera or T-lymphocyte 
conditioned media was added directly to the cells.  At 48 hr post-transfection, samples 
were harvested, washed in cold 1x PBS and lysed with 500μl of passive lysis buffer 
(Promega, Madison, WI, USA). 25 μl of cell extract was used in triplicate on white 96 
well plates to measure NF-kB luciferase activity according to the dual-luciferase reporter 
assay system protocol (Promega).  The NF-kB firefly luciferase activity was standardized 
to Renilla luciferase activity and represented as standardized luciferase units (SLU). 
2.2.6 Immunofluorescence  
LNCaP and RWPE-1 cells were cultured directly on an 8-chamber glass Lab Tek™ 
II Chamber Slide System in a density of 1 x 104 cells per chamber.  Cells were exposed to 
10% sera, conditioned media, or serum free media.  Control cells were cultured in 
complete (10% FBS) RPMI or serum free RPMI.  After recovery, slides were fixed in 4% 
paraformaldehyde/PBS, blocked in aldehyde blocking solution (100 mM glycine/PBS) 
and permeabilized in a 0.1% Trition X-100/PBS solution at room temperature for 5 min.  
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To determine localization of NF-κB, cells were probed with rabbit anti-p65 (Santa Cruz; 
sc-372).  FITC and/or Cy3-conjugated donkey anti-rabbit secondary antibodies (Jackson 
ImmunoResearch Laboratories) allowed fluorescent detection of primary antibodies on 
a Zeiss Axiovert 40 inverted microscope.  Cells were counterstained, with 200 ng/ml 
DAPI, for detection of cellular nuclei. Images of control and experimental cells were 
acquired under identical exposure conditions in three independent experiments to 
ensure reproducibility [61] . 
2.2.7 Western blot analysis 
Western blot analysis was performed as previously described [61].  Briefly, 
prostate cells were serum-treated directly or with conditioned media from stimulated T-
lymphocytes, harvested and lysed in Laemmli lysis buffer for SDS-polyacrylamide gel 
electrophoresis and probed with: rabbit anti-BCL-Xl, rabbit anti-MCL-1, rabbit anti-
GAPDH  (all Cell Signaling, Boston, MA, USA), rabbit anti-actin (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), rabbit anti-Cyclin D1 (Millipore, Billerica, MA).  
Luminescent signal was detected on a Syngene imaging system and quantitative 
densitometric analysis measured using GeneTools. 
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2.2.8 Statistics  
Values are presented as mean ± standard error of the mean (SEM).  For the 
Western blot analyses and luciferase assays, means were compared across treatment 
groups using Student's t-test and p ≤ 0.05 was considered statistically significant. 
2.3 Results 
2.3.1 Aging mimic GPAT-1 -/- T-lymphocytes have a pro-inflammatory cytokine profile  
Previously we have demonstrated that GPAT-1 regulates proliferation and 
cytokine production in T-lymphocytes [30].  Without GPAT-1 TH1 (IL-2 and IFN-gamma) 
cytokine secretion is reduced and TH2 (IL-4 and IL-10) cytokine secretion is increased 
[30].  To further characterize and compare the relative cytokine expression profile from 
T-lymphocytes of young GPAT-1-/- (KO) mice to those derived from young and old (>22 
month) wild-type (WT) mice, we utilized a cytokine immunoarray which is capable of 
simultaneously detecting different cytokines and chemokines.  Consistent with our 
previous observation, GPAT-1-/- T-lymphocytes resembled the inflammatory phenotype 
that is characteristic of aged murine T-lymphocytes (Fig 2.1).  While many of the 
cytokines and chemokines were at similar levels among the three groups (IL-1α and IL-
1β, for example), the knock-out and old mice trended together, such as with MIP-1α and 
β, RANTES, IL-3 and I-309.  Of note, compared to that found in the WT young mice, 
levels of IL-17 were 12-and 8-fold higher in the GPAT-1-/- (KO) and old mice, respectively.  
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Intriguingly, while IL-6 levels were 12-fold higher in the old mice, the levels were 
comparable between the WT and KO mice, suggesting that any observed phenotype 
with the KO is independent from IL-6 activity. 
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Figure 2.1 Aging mimic GPAT-1 -/- T-lymphocytes have a pro-inflammatory cytokine 
profile.  
Secreted cytokine immunoarray profile of isolated and anti-CD3/CD-28 stimulated 
splenic T-lymphocytes derived from wild type (WT, black bars), old (light gray bars) and 
GPAT-1−/− (KO, dark gray bars) mice. After stimulation, T-lymphocytes were cultured in 
serum free media for 24 hr. Factors secreted into the serum free media (conditioned 
media) were incubated on the immunoarray to detect relative expression of indicated 
cytokines and chemokines. Levels were standardized relative to negative control. 
40 
 
2.3.2 GPAT-1-/- and old wild type T-lymphocytes secrete factors that induce NF-B 
activity 
NF-B is a transcription factor that modulates the expression of many genes 
associated with inflammatory processes, cell adhesion, differentiation, proliferation, 
angiogenesis and apoptosis.  Dysregulation of NF-B has been implicated as a leading 
cause in the development of many diseases, including cancer [62-65].  In the prostate, 
upregulation of NF-κB is associated with increased inflammation, prostate 
carcinogenesis, progression to hormone independence and increased metastatic 
potential [66-68].  Therefore, to determine if circulating factors in the sera from aged or 
GPAT-1 -/- mice induce NF-κB activity in non-transformed prostate epithelial and 
prostate cancer cells, we exposed these cell lines to 10% sera from WT young, old or 
young GPAT-1-/- (KO) mice. An NF-B luciferase reporter assay was used to measure NF-
κB transcription activity (Fig 2.2).  Exposure to either sera from old mice or GPAT-1 KO 
sera resulted in a significant increase in NF-κB activity in the PC-3 (50% and 100%, 
respectively) and LNCaP (75% and 400%, respectively) prostate cancer cell lines 
compared to sera from the young WT mice (P<0.05) (Fig 2.2A), suggesting that 
circulating factors in the sera of GPAT-1-/- mice mimic those in the aged mice in 
promoting NF-κB transcriptional activity.  The same trend between the WT and KO mice 
was observed in the primary and non-transformed prostate cell lines PReC and RWPE-1 
respectively (Fig 2.2B).  These data indicate that circulating factors associated with an 
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aging T-cell induce activation of NF-κB, a critical step in prostate cancer initiation, not 
only in cancer cells but also in non-cancer cells. 
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Figure 2.2 Effect of circulating factors in the sera from the aged wild type and aging-
mimic young GPAT-1 -/- mice on NF-κB transcriptional activity.  
 
Dual-Luciferase assay was used to measure NF-kB transcriptional activity in response to 
10% FBS or sera from young wild-type, old or GPAT-1 -/- mice in A) PC3 and LNCaP 
prostate cancer cells or B) non-cancerous PrEC and RWPE-1 prostate epithelial cells. 
Presented is the combined average of three independent experiments and bars 
representing the standard error of the mean. Means with different letters are 
significantly different (p <0.05). 
43 
 
2.3.3 Circulating factors in the sera from mice with an aged immune system induce 
nuclear translocation of NF-B  
NF-B is a heterodimeric complex consisting of the p50 and p65 subunits.  When 
bound by I-B, NF-B is excluded from the nucleus and remains in the inactive state.  
Engagement of membrane based receptors initiates activation of the I-B kinase (IKK) 
complex which phosphorylates I-kB at two key serine residues, targeting it for 
proteasomal degradation through the ubiquitin ligase pathway.  The liberated NF-B 
complex is then free to translocate into the nucleus, and bind to NF-B response 
elements, thereby modulating gene expression [69].  To determine the effect of sera 
from GPAT-1-/- (KO), young WT or old mice on the subcellular localization of NF-B, 
immunofluorescence was used to visualize changes in p65 subcellular 
compartmentalization.  As seen in Figure 2.3, sera from the young GPAT-1-/- mice (iii and 
iv) induced translocation of p65 into the nucleus in both the LNCaP cancer cell line (Fig 
2.3A) and non-cancerous RWPE-1 cell line (Fig 2.3B), while the sera from WT young mice 
(i and ii) primarily showed cytosolic (inactive p65) staining.  Importantly, results with the 
old WT mice (v and vi) in the LNCaP and RWPE-1 cells correlate with those obtained 
with the young GPAT-1-/- mice, strongly supporting the results obtained with the 
luciferase reporter studies.  
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Figure 2.3 Alteration of NF-kB subcellular localization induced by circulating factors in 
the sera from aged and young GPAT-1-/- mice.  
 
Immunofluorescence was used to visualize NF-B localization (red) A) in LNCaP cells or 
B) non-cancerous RWPE-1 prostate epithelial cells exposed to sera from WT young (i), 
GPAT -/- (KO) (iii), old WT (V) mice. (ii), (iv) and (vi) are the images merged with the DAPI 
stain (blue), indicating cellular nuclei. Presented is a representative of three 
independent experiments. 
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2.3.4 Factors secreted from aging T-lymphocytes induce NF-kB transcriptional activity 
Based on our observation that circulating factors from the sera of GPAT-1-/- mice 
induced NF-B activation similar to that of old mice, we sought to determine whether 
factors originating from the T-lymphocytes alone were impacting NF-B activity.  Splenic 
T-lymphocytes were isolated from the respective mice then stimulated with or without 
anti-CD3/CD28 antibodies. After 24 hours stimulation, conditioned media from the T-
lymphocytes was collected. The conditioned media from the stimulated and 
unstimulated T-lymphocytes was then used to culture primary non-transformed (RWPE-
1) and prostate cancer (LNCaP) cell lines and NF-κB activity measured as in Figure 2 (Fig 
2.4).  Factors secreted into the conditioned media from GPAT-1-/- and old wild type T-
lymphocytes induced a 3-fold and 2-fold induction of NF-κB, respectively, in the LNCaP 
cell line compared to those in the conditioned media from a young WT mice (p < 0.05) 
(Fig 2.4A) and more than 7-fold higher in the RWPE-1 cells exposed to conditioned 
media from GPAT-1-/-  when compared to those exposed to conditioned from wild type 
young mice (p< 0.05) (Fig 2.4B). Notably, results with the old WT mice in the in RWPE-1 
cells (Fig 2.4B) correlate with those obtained with the young GPAT-1-/- mice. This 
suggests that the aged and GPAT-1-/- T-lymphocytes directly modulate NF-B activity in 
prostate epithelial and prostate cancer cells.  
Additionally, fluorescence microscopy was performed to visualize p65 subcellular 
localization in response to exposure to the conditioned media. As seen in Figure 2.5A, 
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LNCaP cells display evidence of nuclear translocation of NF-κB in response to 
conditioned media from stimulated T-lymphocytes from young GPAT-1-/- (Fig 2.5v) and 
old wild-type mice (Fig 2.5Avi).  Similar results were obtained with the non-cancerous 
RWPE-1 cells (Fig 2.5B). Nuclear translocation of NF-κB correlates with the strong 
induction of NF-κB transcriptional activity that was observed when LNCaP prostate 
cancer cells were exposed to conditioned media from stimulated aged wild type T-
lymphocytes. 
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Figure 2.4 Effect of isolated splenic T-lymphocyte-secreted factors from WT or young  
GPAT-1 -/- mice on NF-B transcriptional activity 
 LNCaP prostate cells (A) and RWPE-1 non-transformed prostate epithelial cells (B)were 
used. Dual-Luciferase assay was used to measure NF-kB transcriptional activity in 
response to conditioned media (CM) generated from anti-CD3 plus CD-28 stimulated 
cultured splenic T-lymphocytes from either young GPAT- -/-  (KO), young wild-type (WT) 
or old wild type mice. Means with different letters are significantly different (p <0.05). 
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Figure 2.5 Nuclear localization of NF-kB induced by factors secreted from stimulated 
aged T-lymphocytes.  
Immunofluorescence was used to visualize NF-kB localization (red) A) in LNCaP cell or B) 
non-cancerous RWPE-1 prostate epithelial cells  in response to exposure to conditioned 
media generated from unstimulated (upper panel) and stimulated (lowerpanel) 
Tlymphocytes isolated from wild-type (WT Young) (i) and (iv), GPAT -/- (KO) (ii) and (v) 
and wild-type old (Old) (iii) AND (vi) mice. DAPI staining (blue) indicates cellular nuclei 
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2.3.5 Factors secreted by aging T-lymphocytes upregulate the expression of key 
downstream targets of NF- B 
NF-kB regulates the transcription of several genes involved in the suppression of 
cell death, proliferation and tumor promotion [38]. BCL-xL is one of the key downstream 
gene targets of NF-kB that promotes survival [70]. MCL-1, an important target gene of 
NF-kB, is an anti-apoptotic factor implicated in the survival of prostate cancer cells [70].  
In addition to the regulatory role it plays in apoptosis, NF-κB is also capable of 
promoting cell cycle progression by modulating the expression of cell cycle specific 
genes, including cyclin D1[71]. Recent studies suggest that NF-κB-induced cyclin D1 
expression is a key contributing element in mammary breast carcinogenesis [71-73] .  
Immunoblot analysis (Fig 2.6) shows that expression levels of key NF-κB genes (MCL-1, 
Cyclin D1, BCL-xL) are upregulated in LNCaP cells (30%, 40% and 10% ) and RWPE-1 cells 
(15%, 35% and 60%, respectively) exposed to KO sera compared to levels observed with 
exposure to WT sera after treatment for 48 hours with 10% sera or conditioned media 
from the young GPAT-1-/- mice. Based on our observation that circulating factors from 
the sera of GPAT-1-/- mice induced activation of important targets of NF-κB, we sought 
to determine whether factors specifically originating from the T-lymphocytes impact 
regulation of key downstream targets of NF-κB. Splenic T-lymphocytes were isolated 
from the respective mice then stimulated with or without anti-CD3/CD28 antibodies. 
After 24 hours stimulation, conditioned media from the T-lymphocytes was collected. 
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The conditioned media from the stimulated and unstimulated T-lymphocytes was then 
used to culture primary non-transformed (RWPE-1) and prostate cancer (LNCaP) cell 
lines and western blot analysis was used to measure expression levels of key NF-κB 
genes. Factors secreted into the conditioned media from GPAT-1-/- mice up-regulate the 
expression of MCL-1, Cyclin D1 and BCL-xL in the LNCaP cells by 20%, 60% and 70% and 
by 80%, 66% and 50%, respectively in RWPE-1 cells by compared to those in the 
conditioned media from a young WT mice. Importantly, factors secreted into 
conditioned media from old WT T-lymphocytes also upregulated key NF-κB genes in 
similar ways that the conditioned media from the young GPAT-1-/- mice does (Fig 2.7).  
 
 
 
 
 
 
 
 
 
 
 
51 
 
A.  LNCaP
B. RWPE-1
0
0.5
1
1.5
WT KO
R
e
la
ti
ve
 P
ro
te
in
 L
e
ve
ls
Cyclin D1 
0
1
2
3
4
WT KO
R
el
at
iv
e 
P
ro
te
in
 L
ev
el
s
BCL-xL
0
0.5
1
1.5
WT KO
R
el
at
iv
e 
P
ro
te
in
 L
ev
el
s
MCL-1
0
0.5
1
1.5
2
WT KO
R
el
at
iv
e 
 P
ro
te
in
 L
ev
el
s
Cyclin D1
0
0.5
1
1.5
2
2.5
WT KO
R
el
at
iv
e 
P
ro
te
in
 L
ev
el
s
BCL-xL
0
1
2
3
4
5
WT KO
R
el
at
iv
e 
P
ro
te
in
 L
ev
el
s
MCL-1
 
Figure 2.6 Increased expression of gene targets of NF-κB in response to circulating 
factors secreted from aged-mimic T-lymphocytes.  
 
Immunoblot detection of MCL-1, Cyclin D1 and BCL-1-xL expression levels in LNCaP (A) 
and RWPE-1 (B) cells after exposure to 10% sera from young wild-type (WT) or GPAT-1-/- 
(KO) mice. Actin was used as a loading control. Graphs indicate the combined average 
relative densitometry values for three independent experiments, with bars indicating 
the SEM.  
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Figure 2.7 Increased expression of gene targets of NF-κB in response to circulating 
factors secreted from aged-mimic T-lymphocytes.  
 
Immunoblot detection of MCL-1, Cyclin D1 and BCL-xL expression levels in LNCaP (A) 
and RWPE-1 (B) cells after exposure to 10% conditioned media from stimulated wild-
type (WT) T-lymphocytes (+), unstimulated wild-type (WT) T-lymphocytes (-) or 
stimulated (+) and unstimulated (-) GPAT-/- (KO) T-cells. Actin was used as a loading 
control. Graphs indicate the combined average relative densitometry values for three 
independent experiments, with bars indicating the SEM.  
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2.4 Discussion     
The most established risk factors for prostate cancer development include age, 
race/ethnicity, and family history [58]. Longitudinal studies of aging men have revealed 
incidence curves indicating that prostate cancer risk begins to rise sharply after age 55 
and peaks at age 70–74 [1].  Postmortem and histopathologic analysis of human 
prostate specimens provides further evidence of the link between aging and prostate 
cancer incidence [1, 74]. One widely accepted explanation for this association is that the 
slow growth characteristics observed within the prostatic tissue prolongs the time for 
acquired mutations to manifest [75] . To date, many studies have focused on 
distinguishing aggressive from indolent disease, or identifying prognostic biomarkers 
predictive of clinical outcome and survival; however, few studies have investigated the 
potential contribution that the normal aged immune system may have in the 
development of prostatic disease.  While it is well established that age-related changes 
in immune surveillance and response occur, including loss of appropriate T-lymphocyte 
function and immunosenescence, this dysregulation has not yet been correlated with 
development of prostate cancer.  In this investigation, we provide the first evidence that 
age-related T-lymphocyte dysfunction may promote prostate cancer cell survival 
through induction of NF-κB.  
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Pro-inflammatory cytokines can initiate and potentiate the activation of NF-κB, a 
nuclear transcription factor frequently dysregulated in cancer [9, 76].  NF-κB activity in 
turn up-regulates expression of pro-survival factors and cytokines such as survivin and 
interleukins 2, 6, 8 and 9 [77]. Building upon our previous studies demonstrating a 
critical role for NF-κB in prostate cancer cell survival [61], we sought to determine if one 
mechanism by which an aging immune system might contribute to prostate cancer 
initiation and progression is through induction of NF-κB.  Intriguingly, circulating factors 
in the old WT and young GPAT-1-/- mouse sera both induced NF-κB transcriptional 
activity in the PC-3 and LNCaP prostate cancer cell lines, while the young WT mouse sera 
displayed no significant effect, suggesting that the age-specific shift in T lymphocyte 
function may be partly responsible for the increased NF-κB activity. Further, we 
observed a greater than 3-fold induction of NF-κB transcriptional activity in primary and 
immortalized, non-transformed (PrEC and RWPE-1) cells respectively, indicating that 
induction of NF-κB activity by elevated cytokines is not restricted to cancer cells.  This is 
especially important since age is a risk factor for the development of prostate cancer, 
which occurs through transformation of normal epithelial cells. 
The GPAT-1-/- model appears to strongly mimic the phenotypic changes observed 
in the aging immune system, particularly as it relates to T-cell function.  T-lymphocytes 
from young GPAT-1-/- demonstrate reduced IL-2 production and subsequent 
proliferation, altered cytokine production, increased membrane cholesterol to 
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phospholipid ratio and increased activation-induced apoptosis. Additionally, our data 
indicate that T-lymphocytes from GPAT-1-/- mice also closely mimic aged T cells in 
secreted levels of key cytokines and chemokines known to promote tumorigenesis such 
as IL-17, RANTES (CCL5) and I-309 [42, 78, 79].  Intriguingly, while secreted IL-6 levels 
were elevated in the T-cells from the old mice, T-cells from the GPAT-1 -/- mice did not 
demonstrate significantly higher levels compared to the aged-matched wild type mice, 
suggesting that the observed induction of NF-κB activity was independent of IL-6 
activity, possibly through IL-17.  
These data have important implications for our current understanding of the 
contribution of the immune system to prostate cancer development.  Rather than being 
merely a passive component to disease development, our data strongly support the 
concept that the aging immune system actively promotes cancer onset and progression, 
possibly through induction of chronic inflammation in the microenvironment resulting in 
upregulation of pathways leading to neoplastic changes, as has been proposed by 
Sfanos and De Marzo [80].  This change in perspective regarding the role of the aging 
immune system in cancer development opens new avenues for development of 
potential preventive interventions and screening biomarkers, and the results of our 
study suggest a focus on T cell-induced pathways.      
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Chapter 3: Age-related Increase in IL-17 Activates Pro-inflammatory Signaling in 
Prostate Cells 
 3.1 Introduction  
Prostate cancer is mainly a disease of older men [81]. This is due to several 
factors, including an increased duration of carcinogenesis, accumulation of DNA damage 
and an increased susceptibility of aging cells to environmental carcinogens [2]. Another 
mechanism important to the link between aging and prostate cancer is reduced immune 
function in the elderly. Qualitative and quantitative changes in immune response, 
including profound changes in T cell function, are part of the aging process. Age-related 
alterations to T cell immunity include decreased T cell differentiation and increased pro-
inflammatory cytokine secretion [82]. Age is positively correlated with increased 
circulating levels of many pro-inflammatory cytokines such as interleukin-1 beta (IL-1β), 
tumor necrosis factors alpha (TNFα), interleukin-6 (IL-6) and interleukin-17 (IL-17) [83] .  
The inflammatory process is highly implicated in the pathogenesis of many 
common and severe age-related diseases, including prostate cancer [84]. Numerous 
studies have shown considerable evidence for inflammatory conditions being involved 
in the initiation and progression of prostate cancer [80, 85-87]. Furthermore, a large 
number of reports have specifically linked IL-17 to prostate cancer, with IL-17A 
expression increased in more than 50% of prostate cancers [13, 45, 88]. It has also been 
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demonstrated that two IL-17 receptors (IL-17RA and IL-17RC) are expressed in prostate 
cancer [88], and T helper 17 (TH17) cell number is increased in prostate cancer patients 
[45]. Recently, Zhang et al. reported that IL-17 promotes the formation and growth of 
prostate adenocarcinoma in a mouse model of autochthonous prostate cancer [42]. 
Taken together, the present literature suggests a strong link between IL-17 activity and 
prostate cancer development. However, little is known regarding the role of aged 
related increase in circulating IL-17 and regulation of pro-tumorigenic pathways in 
prostate epithelial cells.  
We showed that, for the most part, the T cell cytokine profile of the aging-mimic 
T cell GPAT-/- (AM) mice mirrored that observed in aged wild-type (OLD) mice, including 
higher expression levels of IL-17.  In order to dissect the relationship between aging T 
cells, IL-17 and pro-tumorigenic signaling in prostate cells, we used the young (6 month 
old) glycerol-3-phosphate acyltransferase-1 knock-out KO mouse, which T cells closely 
mimics the immune system of an aged (>22 month old) mouse. Serum and splenic T-
lymphocytes from young (6 month old) wild-type (WT), AM and wild-type old (OLD) 
mice were collected to test the contribution of IL-17 in modulating key signaling 
pathways in prostate tumorigenesis. 
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3.2 Materials and Methods  
3.2.1 Murine Models of an Aging Immune System 
C57BL/6 GPAT-1 +/- mice were obtained from Dr. Rosalind Coleman (University 
of North Carolina at Chapel Hill) and bred in our animal facilities to obtain homozygous 
knock-outs. Mice were fed a commercial chow diet (Prolab Rat/Mouse/Hamster 2000) 
provided by the animal facility. Offspring were numbered to monitor sex differences or 
differences between litters.  Aged (>22 month old) C57BL/6 mice were purchased from 
the National Institute for Aging. Mice were housed on a 12:12-h light-dark cycle and had 
ad libitum access to food and water.   
3.2.2 T-lymphocyte isolation and stimulation  
Splenic T-lymphocytes were isolated from 6 month old WT and KO, and 22 
month old (OLD) wild-type mice using negative selection (Miltenyi magnetic microbeads 
and antibody T-lymphocyte specific antibody combinations) as per the manufacturer's 
instructions, yielding a 95% pure splenic T-lymphocyte population. Isolation by negative 
selection prevents perturbation of the T-lymphocyte's receptor during the isolation 
procedure, as occurs with isolation via positive selection. Lymphocytes were stimulated 
at 37°C in pre-warmed complete RPMI-1640 culture media (10% heat-inactivated fetal 
bovine serum (FBS) plus 100 U/ml penicillin, 100 µg/ml streptomycin, 10 µM 2-
mercaptoethanol, and 100 mM L-glutamine) with either 10 µg/ml plate-bound anti-CD3 
59 
 
and 1 µg/ml anti-CD28 or no stimulation. Anti-CD3 and CD28 antibodies are routinely 
used as polyclonal mitogens to mimic the in vivo T cell response. After 24 hours of 
stimulation, the T lymphocyte culture supernatant (conditioned media) was collected 
and used in subsequent experiments.  All animal procedures were approved by the 
University of Texas Institutional Animal Care and Use Committee. 
3.2.3 Cells and Cell Culture  
The LNCaP prostate cancer cell line was purchased from ATCC (Rockville, MD) 
and grown in RPMI-1640 containing 1% penicillin and streptomycin, supplemented with 
10% FBS in a 5% (v/v) CO2 humidified incubator at 37°C.  The immortalized non-
transformed RWPE-1 prostate epithelial cell line was purchased from ATCC and grown in 
Keratinocyte Serum Free Medium (K-SFM) supplemented with bovine pituitary extract 
(BPE) and human recombinant epidermal growth factor (EGF) in a 5% (v/v) CO2 
humidified incubator at 37°C. The IL-17R shRNA clones (designated shIL-17R1 and shIL-
17R2) were generated by transfecting cells with the IL-17R shRNA Plasmid (h) sc-40037 
(Santa Cruz Biotechnologies, Santa Cruz, CA), using FuGENE HD transfection reagent 
(Roche, Basel, Switzerland) per manufacturer's instructions. Control LNCaP and RWPE-1 
cells (designated shControl) were generated by stably transfecting negative-control 
shRNA plasmids: Control Plasmid-B sc-108065 and Control Plasmid-C sc-108066 (Santa 
Cruz Biotechnologies, Santa Cruz, CA).  Puromycin antibiotic (Santa Cruz 
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Biotechnologies, Santa Cruz, CA) was used to stably select transfected cells. All cells 
were maintained in selective RPMI-1640 or K-SFM media containing 4 µg/ml puromycin. 
RT-PCR was performed to monitor IL-17R gene expression knock-down using the IL-17R 
(h)-PR primer (Santa Cruz Biotechnologies, Santa Cruz, CA). In addition western blot 
analysis was used to confirm knock-down of the IL-17R gene. Antibodies against IL-17R 
antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) and phospho- and total-STAT3 
(Cell Signaling) were used. 
3.2.4 Dual Luciferase assay 
LNCaP and RWPE-1 shIL-17R1, shIL-17R2, and shControl cells were seeded in 6-
well plates and grown to 60–80% confluence for transfection. 1μg NF-B luciferase 
reporter plasmid (Stratagene, La Jolla, CA) and 20ng of control Renilla reporter plasmid 
were concurrently transfected using FuGENE HD (Roche, Basel, Switzerland) transfection 
reagent, according to manufacturer’s protocol. 24 hr post-transfection, 5% sera or T-
lymphocyte conditioned media was added directly to the cells. 48 hr post-transfection, 
samples were harvested, washed in cold 1x PBS and lysed with 500μl of passive lysis 
buffer (Promega, Madison, WI,).  NF-κB luciferase activity was measured according to 
the dual-luciferase reporter assay system protocol (Promega, Madison, WI).  The NF-κB 
luciferase activity was standardized to Renilla luciferase activity. 
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3.3.5 Western blot analysis 
Prostate shIL-17R and shControl cells were exposed for 48 hours to sera or 
conditioned media from stimulated T-lymphocytes, then harvested and lysed in Laemmli 
lysis buffer for SDS-polyacrylamide gel electrophoresis. The lysates were probed with 
the following antibodies: VCAM, FAS, cAIP2 (all Cell Signaling, Boston, MA), cyclin D1 
(Millipore, Billerica, MA), and actin (Santa Cruz Biotechnology, Santa Cruz, CA).  
Luminescent signal was detected on a Syngene (Frederick, MD) imaging system and 
quantitative densitometric analysis measured using GeneTools. 
3.2.6 RT-qPCR 
Prostate Cancer LNCaP cells were exposed to sera for 48 hours. Total RNA was 
isolated with the QIAGEN (Valencia, CA) RNA extraction system according to the 
manufacturer’s instructions and transcribed into complementary DNA (cDNA). Gene 
expression of 84 genes from the QIAGEN NF-κB Signaling Targets RT² Profiler PCR Array 
(Valencia, CA) was quantified by QIAGEN SYBR green real-time PCR on an Eppendorf 
instrument (Santa Clara, CA). Nonspecific signals caused by primer dimers were 
excluded by dissociation curve analysis and use of non-template controls. To normalize 
for loaded cDNA, actin was used as an endogenous control. 
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3.2.7 MTT Cell Proliferation Assay 
Cells were seeded in at a density of 8 × 103 in 96-well plates. After 24 hours of 
growth in 10% FBS media, the cells were exposed experimental conditions for 96 hours. 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT reagent in PBS 
(5 mg/ml) was then added to each well to a final concentration of 0.5 mg/ml. After 
three hours of incubation in a CO2 humidified incubator at 37°C, the MTT containing 
media was removed and 200 ul dimethyl sulfoxide (DMSO) was added. Absorbance was 
read at 570 nm on a FLUOstar Omega Spectrometer (BMG Labtech, Offenberg, 
Germany). Relative cell proliferation was calculated by dividing each absorbance value 
by the absorbance for shControl cells grown in young WT sera or CM. 
3.2.8 Statistics  
Values are presented as mean ± standard error of the mean (SEM).  For the 
Western blot analyses, MTT assays and Luciferase assays, means were compared across 
treatment groups using Student's t-test and one-way ANOVA Multiple Comparison was 
used for comparing more than two conditions. P≤0.05 was considered statistically 
significant 
63 
 
 3.3 Results  
3.3.1 IL-17 in the sera from Aging Mimic mice induces NF-B activity in prostate 
epithelial cells  
NF-κB is a transcription factor that modulates the expression of many genes 
associated with inflammatory processes, cell adhesion, differentiation, proliferation, 
angiogenesis and apoptosis. In the prostate, upregulation of NF-κB is associated with 
increased inflammation, prostate carcinogenesis and increased metastatic potential 
[63]. We determined that circulating factors in the sera from OLD or AM mice induce 
NF-κB activity in non-transformed RWPE-1 prostate epithelial and LNCaP prostate 
cancer cells (Fig.2.2). To confirm that IL-17 in the sera from AM mice was in part 
responsible for the observed activation of NF-κB in prostate epithelial cells, shRNA was 
used to knock down the IL-17 receptor (IL-17R) in RWPE-1 and LNCaP cells and make 
stable IL-17R knock-down clones (shIL-17R1 and shIL-17R2). Clones of RWPE-1 and 
LNCaP cells transfected with a control shRNA (shControl) were also generated to serve 
as the negative control for comparison. IL-17R knock-down was confirmed by western 
blot analysis of IL-17R protein expression levels (Fig 3.1A), and qPCR determination of IL-
17R mRNA levels (Fig 3.1B).  
To further characterize our IL-17R shRNA clones, we assessed whether IL-17R 
knock-down in human prostate cells inhibits the activation STAT3, its downstream 
target. In the absence of IL-17R, IL-17-induced STAT3 activity was diminished by 3- and 
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6-fold in RWPE-1 cells and LNCaP cells respectively. However, addition of interleukin-6 
(IL-6), which has been shown to activate STAT3, did not diminish STAT3 activity in the IL-
17R shRNA clones, demonstrating the specificity of the knock-down (Fig 3.2). 
 Next, the IL-17R shRNA clones were exposed to sera from WT, AM or OLD mice 
and an NF-B luciferase reporter assay was used to measure NF-κB transcriptional 
activity (Fig 3.3). In chapter 2, I established that exposure to sera from KO versus young 
WT mice results in a significant increase in NF-κB activity in LNCaP and RWPE-1 cells (Fig 
2.1). Importantly, in the absence of IL-17R (shIL-17R1 and shIL-17R2), NF-κB activity was 
significantly diminished by 47% in LNCaP cells exposed to sera from AM mice (Fig 3.3A). 
In the absence of IL-17R (shIL-17R1 and shIL-17R2) OLD sera was still able to promote 
NF-κB activity. Sera form OLD mice have additional cytokines that could be promoting 
NF-κB activity in the absence of IL-17. A similar trend was observed in the RWPE-1 cell 
shIL-17R clones, where NF-κB activity was reduced by 50% when IL-17R was absent in 
the cells exposed to sera from AM mice (Fig 3.3B). Exposure to sera from OLD versus 
young WT mice increases NF-κB activity in RWPE-1 cells by 1.5-fold. In the absence of IL-
17R (shIL-17R1 and shIL-17R2), NF-κB activity was significantly diminished by 20% in 
RWPE-1 cells exposed to sera from AM mice. Taken together, these data indicate that 
the aged-T cell-related up-regulation of IL-17 can promote NF-κB activation in prostate 
cancer cells as well as in non-cancerous prostate epithelial cells.  
 
65 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
shControl shIL-17R1 shIL-17R2
IL
-1
7
R
 m
R
N
A
 le
ve
ls
b
a
b
B
A LNCaP RWPE-1
0
0.2
0.4
0.6
0.8
1
shControl shIL-17R1 shIL-17R2
IL
-1
7
R
 m
R
N
A
 le
ve
ls
 a
b
b
IL-17R
Actin
0
20
40
60
80
100
120
shControl shIL-17R1 shIL-17R2
R
e
la
ti
ve
 I
L1
-7
R
  p
ro
te
in
  
Le
ve
ls
 
c
0
20
40
60
80
100
120
shControl shIL-17R1 shIL-17R2
R
e
la
ti
ve
 I
L-
1
7
R
 p
ro
te
in
 
le
ve
ls
b
a
b
a
b
 
 
Figure 3.1 IL-17R expression in human prostate cells. 
 IL-17R protein expression levels  were determined by western blot analysis (A) in LNCaP  
prostate cancer cells transfected with IL-17R shRNA (designated shIL-17R1 and shIL-
17R2) or control shRNA  (shControl) (left)  and RWPE-1 prostate epithelial cells 
transfected with IL-17R shRNA or control shRNA (right). Graphs indicate the average 
relative densitometry values from three independent experiments. IL-17R mRNA levels 
was determined by qPCR (B). Different letters indicate statistically significant differences 
(p<0.05) 
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Figure 3.2 Expression levels of pSTAT3 in response to IL-17R knock-down.  
Protein expression levels of pSTAT3, relative to tSTAT3, were detected by immunoblot in 
LNCaP (left) and RWPE-1 (right) cells transfected with IL-17R shRNA (shIL-17R1 and shIL-
17R2) or control shRNA (shControl) after exposure to 100ng/ml IL-17 or IL-6.  Graphs 
indicate the combined average relative densitometry values from three independent 
experiments, with different letters indicating statistically significant differences 
(p<0.05). 
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Figure 3.3 NF-κB transcriptional activity is stimulated by IL-17 in the sera of Aging 
Mimic mice.  
 
NF-κB transcriptional activity was measured by dual luciferase assay in response to sera 
from young wild-type (WT), old wild-type (OLD) or Aging Mimic GPAT -1 -/- (AM) in 
LNCaP (A) or RWPE-1 (B) cells transfected with IL-17R shRNA (shIL-17R1 and shIL-17R2) 
or control shRNA (shControl). Presented is the average of three independent 
experiments standardized to WT shControl. Different letters indicate statistically 
significantly differences (p<0.05).  
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3.3.2 IL-17 secreted from aging T-lymphocytes induce NF-B transcriptional activity 
Based on our observation that IL-17 in the sera of AM mice induced NF-κB 
activation we sought to determine whether IL-17 originating from the T-lymphocytes 
alone was impacting NF-κB activity.  Splenic T-lymphocytes isolated from young WT and 
AM mice as well as old mice were stimulated with anti-CD3/CD28 antibodies, and 
conditioned media (CM) from the T-lymphocytes was collected after 24 hours. NF-B 
activity was then measured in RWPE-1 and LNCaP cell IL-17R shRNA clones (shIL-17R1 
and shIL17-R2) and control shRNA clones (shControl) following exposure to this CM (Fig 
3.4). LNCaP shIL-17R2 clone exposed to AM or Old T-lymphocyte CM induced almost 
50% less NF-κB activity as compared to the LNCaP shControl clones under the same 
treatment conditions (Fig 3.4A). RWPE-1 shIL-17R2 clones also exhibited around 20% 
less NF-B activity in comparison to RWPE-1 shControl clones after exposure to AM T-
lymphocyte CM (Fig 3.4B).  This suggests that IL-17 secreted from the AM –or OLD T-
lymphocytes directly modulates NF-κB activity in prostate cells. 
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Figure 3.4 IL-17 secreted by isolated splenic T-lymphocytes from wild-type, aging-
mimic or old mice induces NF-κB transcriptional activity.  
Conditioned media (CM) was generated from anti-CD3 plus CD-28 stimulated splenic T-
lymphocytes from young Aging Mimic (AM), young  wild-type (WT) or old wild-type mice 
(OLD). Dual luciferase assay was then used to measure NF-κB transcriptional activity in 
LNCaP (A) or RWPE-1 (B) cells expressing IL-17R shRNA (shIL-17R1 and shIL-17R2) or 
Control shRNA (shControl) following exposure to this CM. Presented is the average of 
three independent experiments standardized to WT shControl. Different letters indicate 
statistically significantly differences (p <0.05).  
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3.3.3 IL-17 secreted by aging T-lymphocytes regulates the expression of key 
downstream targets of NF-κB 
  NF-κB PCR arrays were used to demonstrate the impact of circulating factors in 
the AM versus WT mouse sera on NF-κB target gene expression in LNCaP cells (Fig 3.5A). 
NF-кB regulates the transcription of several genes involved in tumor promotion. 
Notably, several NF-κB target genes involved in the suppression of cell death, promotion 
of inflammatory processes and regulation cell adhesion were upregulated by the sera 
from the AM mouse (Table 3.1). Baculoviral IAP repeat-containing protein 3 (cIAP2), a 
key gene NF-κB target gene that promotes survival of prostate cancer cells by interfering 
with the activation of caspases [89], was upregulated in LNCaP cells exposed to sera 
from the AM mouse (Fig 3.5B). In prostate cancer, increased expression of cIAP2 has 
been found in biopsy specimens from all stages of the disease, suggesting an important 
role in development and progression [90]. In addition to the regulatory role it plays in 
apoptosis, NF-κB is also capable of promoting cell cycle progression by modulating the 
expression of cell cycle specific genes, including cyclin D1 [71, 91] . Cyclin D1 gene 
expression was also upregulated in LNCaP cells exposed to sera from AM mouse (Fig 
3.5B). Various studies have suggested that NF-κB-induced cyclin D1 expression is a key 
contributor in prostate carcinogenesis [71-73, 91] . NF-κB also regulates the expression 
of vascular cell adhesion protein 1 (VCAM-1), an important mediator of cell adhesion in 
many tumors, including prostate carcinomas [92]. Certain tumor cells can use VCAM-1 
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to adhere to the endothelium and recruit monocytes, aiding tumor growth [92-94]. 
Exposure to sera from AM mouse up-regulated the expression of VCAM-1 in LNCaP cells 
(Fig 3.5B). FAS gene expression was also up-regulated in LNCaP cells exposed to sera 
from AM mice. FAS is a type-II transmembrane protein that belongs to the tumor 
necrosis factor (TNF) family. Binding of FAS to its receptor induces apoptosis.  
Immunoblot analysis (Fig 3.6) confirmed that expression levels of key NF-κB 
genes (VCAM-1 and cIAP2) were upregulated in LNCaP cells (by 9% and 40%, 
respectively) when exposed to AM versus WT mouse sera. In contrast, the pro-apoptotic 
protein FAS was downregulated by 29% after treatment with AM mouse sera. A similar 
trend was observed when sera from OLD mice were exposed to LNCaP cells. 
Immunoblot analysis (Fig 3.6) showed that expression levels VCAM-1 and cIAP2 were 
upregulated in LNCaP cells (by 29% and 66%, respectively) when exposed to OLD versus 
WT mouse sera. Exposure to sera from AM, WT or OLD mice did not have a significant 
effect on regulation of Cyclin D1 protein levels in LNCaP cells. Based on our previous 
observation that IL-17 in the AM mouse sera induces NF-κB activation, we examined 
whether IL-17R knock-down impacts the expression of key NF-κB target genes. Our 
results showed that IL-17R knock-down in LNCaP cells decreased expression levels of 
VCAM-1 and cIAP2 (by 26% and 53%, respectively) following exposure to AM mouse 
sera. Knocking-down IL-17R in LNCaP cells did not modulate VCAM-1 expression in 
LNCaP cells exposed to sera from OLD mice. However, IL-17R knock-down in LNCaP cells 
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decreased expression levels of cIAP2 by 66% following exposure to OLD mouse sera. 
Interestingly, FAS expression levels were increased by 8% in LNCaP cell IL-17R shRNA 
clones (shIL-17R1 and shIL17-R2) exposed to OLD mouse sera (Fig 3.6B). Our results 
showed that expression levels of key NF-κB genes (VCAM-1 and cIAP2) were also 
upregulated in RWPE-1 cells (by 28% and 19%, respectively) when exposed to AM versus 
WT mouse sera (Fig 3.7). IL-17R knock-down in RWPE-1 cells decreased expression 
levels of VCAM-1 and cIAP2 (by 75% and 73%, respectively) following exposure to AM 
mouse sera (Fig 3.7). FAS was down-regulated in RWPE-1 cell by 63% after treatment 
with AM mouse sera. IL-17R knock-down in RWPE-1 cells increased expression levels of 
FAS by 57% following exposure to AM mouse sera. A similar trend was observed when 
RWPE-1 cells were exposed to sera form OLD mice. However, IL-17R knock-down in 
RWPE-1 cells did not decrease the expression levels of VCAM-1 after exposure to sera 
from OLD mice (Fig 3.7). Taken together, our results suggest that IL-17 in the sera from 
AM mice is playing an important role in the regulation of key NF-κB target genes 
involved in prostate tumorigenesis. 
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Figure 3.5 Sera from aging-mimic mice up-regulates the expression of key downstream 
targets of NF-κB.  
 
NF-κB PCR arrays revealed NF-κB gene targets that are differentially regulated in LNCaP 
cells in response to circulating factors in the sera from Aging Mimic (AM) versus wild-
type (WT) mice. The relative expression level for each gene in the two samples is plotted 
against each other in the scatter plot (A). Graphs show the relative mRNA levels of key 
NF-kB gene targets (IAP2, CyclinD1, VCAM-1 and FAS) (B) 
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Table 3.1 Sera from Aging Mimic mice differentially regulates the expression of 
downstream targets of NF-κB 
 
Gene Name Fold Up or Down regulation (AM/WT) 
ADM -1.04 
AGT 4.72 
AKT1 12.64 
ALDH3A2 89.26 
BCL2A1 2.31 
BCL2L1 1.87 
BIRC2 1.29 
BIRC3 7.46 
C3 5.17 
CCL11 N/A 
CCL2 8.40 
CCL22 -1.87 
CCL5 7.26 
CCND1 6.23 
CCR5 -1.16 
CD40 1.54 
CD69 -1.67 
CD80 -1.21 
CD83 2.14 
CDKN1A -1.44 
CFB 6.45 
CSF1 4.32 
CSF2 -2.10 
CSF2RB 1.85 
CSF3 -1.03 
CXCL1 N/A 
CXCL10 -7.46 
CXCL2 1.80 
CXCL9 -1.54 
EGFR 1.95 
EGR2 -24.93 
F3 -1.01 
F8 2.25 
FAS 3.92 
FASLG -1.30 
IL1RN 12.64 
ICAM1 5.24 
IFNB1 N/A 
INFNG -3.32 
IL12B -1.62 
IL15 3.39 
IL1A -1.11 
IL1B 8.69 
IL1R2 -1.93 
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IL2 1.22 
IL2RA N/A 
IL4 1.68 
IL6 N/A 
IL8 340.14 
INS 1.31 
IRF1 8.17 
LTA -1.74 
LTB 18.13 
MAP2K6 -2.01 
MMP9 -1.54 
MYC -2.41 
MYD88 1.43 
NCOA3 1.48 
NFKB1 6.50 
NFKB2 4.29 
NFKBIA 29.45 
NQO1 -1.49 
NR4A2 4.86 
PDGFB 1.54 
PLAU -1.27 
PTGS2 -2.07 
REL 2.11 
RELA 2.69 
RELB 16.56 
SELE 2.75 
SELP 1.38 
SNAP25 -1.11 
SOD2 7.31 
STAT1 1.06 
STAT3 2.33 
STAT5B 1.97 
TNF 15.03 
TNFRSF1B 3.32 
TNFSF10 1.27 
TP53 2.27 
TRAF2 4.41 
VCAM1 41.36 
XIAP 2.20 
B2M -1.15 
HPRT1 3.46 
RPL13A -1.21 
GAPDH -1.56 
ACTB -1.60 
Table 3.1 Effects of sera from aging-mimic mice on the expression of downstream 
targets of NF-B. LNCaP cells were exposed to sera from Aging Mimic (AM) or wild-type 
(WT) mice and the transcription of downstream targets of NF-B was analyzed by qPCR. 
The table shows fold-change differences between the AM and WT samples in expression 
of 86 different NF-κB target genes. Statistically significant difference are indicated in 
bold (p<0.05). 
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Figure 3.6 Effects of IL-17 in the sera from aging-mimic mice on expression of key 
downstream targets of NF-κB.  
 
Expression levels of cIAP2, VCAM-1, Cyclin D1 and FAS in LNCaP cells expressing IL-17R 
shRNA (shIL-17R1 and shIL-17R2) or Control shRNA (shControl)  were detected by 
immunoblot after exposure to sera from young wild-type (WT), old wild-type (OLD) or 
Aging Mimic (AM) mice (A). Graphs show the average relative densitometry values for 
three independent experiments. Different letters indicate statistically significant 
differences (p<0.05) (B) 
77 
 
cIAP2
VCAM-1
FAS
Cyclin D1
Actin
A                                                         RWPE-1
shControl shIL17R1                            shIL17R2                             
WT           AM         OLD          WT          AM         OLD          WT          AM        OLD 
B 
0
20
40
60
80
100
120
140
shCont. shIL17R1 shIL17R2
cI
A
P
2 
ex
p
re
ss
io
n
 le
ve
ls
 (
%
)
WT AM OLD
b
c
a
b
d
e c
d
a,e
0
20
40
60
80
100
120
140
160
shCont. shIL17R1 shIL17R2
V
C
A
M
-1
 e
xp
re
ss
io
n
 le
ve
ls
 (
%
)
WT AM OLD
a
b
c
a,c
d
a
c,e
d
e
0
20
40
60
80
100
120
shCont. shIL17R1 shIL17R2
FA
S 
ex
p
re
ss
io
n
 le
ve
ls
 (
%
)
WT AM OLD
c
c
a
b
a
a a
c
c
0
20
40
60
80
100
120
140
160
shCont. IL17R1 IL17R2
C
yc
lin
D
1 
ex
p
re
ss
io
n
 e
ve
ls
(%
)
WT AM OLD
b
b
c
c c
a
a
c c
 
Figure 3.7 Effects of IL-17 in the sera from aging-mimic mice on expression of key 
downstream targets of NF-κB.  
 
Expression levels of cIAP2, VCAM-1, Cyclin D1 and FAS in RWPE-1 cells expressing IL-17R 
shRNA (shIL-17R1 and shIL-17R2) or Control shRNA (shControl)  were detected by 
immunoblot after exposure to sera from  young wild-type (WT), 22-month old wild-type 
(OLD) or  Aging Mimic (AM) mice (A). Graphs show the average relative densitometry 
values for three independent experiments. Different letters indicate statistically 
significant differences (p<0.05) (B).  
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3.3.4 The aging-associated increase in T-lymphocyte IL-17 secretion moderately 
mediates prostate cancer cell proliferation  
After observing that IL-17 in the AM mouse sera regulates the transcription of 
several genes involved in proliferation and tumor promotion, we examined the effect of 
aging-associated circulating IL-17 on prostate cell proliferation. MTT assay was used to 
measure proliferation of the prostate cell lines. Exposure to AM mouse sera increased 
proliferation in LNCaP (Fig 3.8A) and RWPE-1 (Fig 3.8B) cells by 20% and 15%, 
respectively, in comparison to WT mouse sera.  However, AM mouse sera-induced 
proliferation was decreased by 40% in shIL-17R1, 20% in shIL-17R2 and 18% in shIL-
17R1, 13% in shIL-17R2 in LNCaP and RWPE-1 cells, respectively (Fig 3.8). Collectively, 
these results suggest that IL-17 in the AM mouse sera promotes prostate cancer cell 
proliferation, but has only minor effect on normal prostate epithelial cell proliferation.   
Based on our observation that IL-17 in the AM T-lymphocyte CM induced NF-κB 
activation (Fig 3.4), we also investigated whether IL-17 specifically originating from T-
lymphocytes promotes prostate cell proliferation. LNCaP and RWPE-1 cells transfected 
with IL-17R shRNA or control shRNA were exposed to CM from stimulated T-
lymphocytes from young WT and AM as well as old mice. AM and old CM stimulated 
greater proliferation in the shControl LNCaP cells in comparison to WT CM. This 
enhanced proliferation was slightly reduced by IL-17R knock-down in the LNCaP (Fig 
3.9A). In contrast, AM and old CM did not induce significantly greater proliferation in 
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the shControl RWPE-1 cells in comparison to WT CM, and IL-17R knock-down had no 
significant effect on RWPE-1 cell proliferation (Fig 3.9B).  Collectively, these results 
suggest that IL-17 originating from AM and Old mouse T-lymphocytes promotes the 
proliferation of prostate cancer cells, but not of non-transformed prostate epithelial 
cells. 
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Figure 3.8 Effect of IL-17 in the sera from Aging Mimic and wild-type mice on cellular 
proliferation.  
 
MTT assay was used to measure cell proliferation in response to sera from GPAT-1-/- 
Aging Mimic (AM), young wild-type (WT) or old wild-type (OLD) in LNCaP (A) and RWPE-
1 (B) cells expressing IL-17R shRNA (shIL17-R1 and shIL-17R2) or Control shRNA 
(shControl). Presented is the average of three independent experiments standardized to 
WT shControl. Different letters indicate statistically significant differences (p<0.05). 
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Figure 3.9 Effect of isolated splenic T-lymphocyte-secreted IL-17 from wild-type, Aging 
Mimic or old mice on cell proliferation.  
 
MTT assay was used to measure cell proliferation in response to conditioned media 
generated from anti-CD3 plus CD-28 stimulated splenic T-lymphocytes from either 
young GPAT-1 -/- Aging Mimic (AM), young wildtype (WT) or old wild-type (OLD) mice. 
Proliferation was assessed in LNCaP (A) and RWPE-1 (B) cells expressing IL-17R shRNA 
(shIL-17R1 and shIL-17R2) or Control shRNA (shControl). Presented is the average of 
three independent experiments standardized to WT shControl.. Different letters 
indicate significant differences (p<0.05).  
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3.4 Discussion 
One of the most significant risk factors for prostate cancer development is age 
[81]. One widely accepted explanation for the association between age and prostate 
cancer is the fact that prostate carcinogenesis is a characteristically long process [75] . 
Another possible mechanism responsible for prostate tumorigenesis in the elderly is 
aging-associated dysregulation of immune function.  To date, multiple studies have 
shown the importance of the immune system in preventing tumor formation [4, 95]. 
However, few studies have investigated the potential contribution of the retention of 
strong inflammatory responses to age-related prostate tumorigenesis. Retention of 
strong inflammatory responses with age, in the absence of counterbalancing and 
beneficial responses from the immune system, may dramatically enhance prostate 
tumorigenesis.  Inflammation is well established to be an amplificatory factor in prostate 
tumorigenesis [80]. Our data suggest that an aging immune system possibly promotes 
prostate cancer onset through induction of chronic inflammation, specifically via 
enhanced NF-κB signaling. In this chapter, I presented data showing the influence of one 
specific cytokine, IL-17, on age-related induction of pro-inflammatory pathways in 
prostate cells. Recent studies by other investigators have demonstrated that IL-17 
becomes dysregulated with age and that the proportion of IL-17 producing cells is 
higher in aged mice than in young ones [80]. Furthermore, various researchers have 
shown that IL-17 promotes the formation and growth of prostate cancer [43, 96, 97]. 
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Therefore, we hypothesized that age-related changes in IL-17 could potentially initiate 
prostate tumorigenesis through the activation of NF-κB [42, 98], which up-regulates the 
expression of pro-tumorigenic factors [42].   
Building upon our data that demonstrated that aging-related factors induce NF-
κB activity and its pro-survival downstream targets, we examined whether an aging 
immune system may contribute to the induction of pro-inflammatory pathways in the 
prostate thought the increased production of IL-17. Intriguingly, knocking down the IL-
17R in LNCaP prostate cancer cells exposed to sera from GPAT-1-/-Aging Mimic (AM) 
mice markedly diminished NF-κB transcriptional activity. This suggests that the aging-
related increase in IL-17 production may be partly responsible for the observed 
induction of NF-κB activity in prostate cancer cells exposed to AM sera. We also 
observed a significant reduction in NF-κB transcriptional activity in non-transformed 
RWPE-1 prostate epithelial cells transfected with IL-17R shRNA and exposed to AM 
mouse sera, indicating that this phenomenon is not restricted to cancer cells, and may 
play a role even during the very early stages of prostate carcinogenesis. We also 
examined the effect of sera from old mice on induction of NF-κB in the prostate. We 
found numerous similarities between the T cell aging-mimic and old mice in terms of 
regulation of NF-kB in prostate epithelial cells. Intriguingly, there were some key 
differences, which may reflect the more systemic events associated with the aging 
process as a whole and the inter-relationship between an aging immune system and the 
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aging tissues. The impact that the sera from old mice have on prostate cancer cells 
represents the actual aging process as a whole, not just the aging T cell population, as 
with our aging-mimic transgenic mice.   
One mechanism by which IL-17 may initiate prostate cancer progression is 
through the regulation of NF-κB target genes that control cancer cell proliferation and 
tumor growth. Our results show that knock-down of the IL-17R in prostate cells 
significantly reduces the aging-induced expression of two key NF-κB target genes, cIAP2 
and VCAM. Moreover, expression of the pro-apoptotic protein FAS is upregulated in 
prostate cancer cells lacking IL-17R. These results have important implications for our 
current understanding of IL-17’s contribution to induction of pro-tumorigenic pathways 
in the prostate, particularly given the changes in pro-inflammatory signaling found in 
non-transformed prostate epithelial cells exposed to AM mouse sera and T-lymphocyte 
CM. Furthermore, the observed increase in prostate cancer cell proliferation upon 
exposure to AM sera was significantly reduced when the IL-17 receptor was knocked 
down, demonstrating that the aging-related up-regulation of T-lymphocyte IL-17 
secretion may play a key role in prostate cancer progression.  
In summary, the present study provides evidence that the aging-associated 
increase in circulating IL-17 promotes pro-inflammatory signaling in prostate epithelial 
cells. T cells from our aging-mimic mice secrete elevated levels of IL-17, possibly due to 
an imbalance in the T Helper 17(TH17)/Regulatory T (Treg) cell ratio, commonly 
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associated with aging, making this an excellent model for the study of age-related 
changes in T-lymphocyte function [45]. The change toward a pro-inflammatory 
phenotype and increased production of IL-17 during aging may be actively promoting 
prostate cancer development via recruitment of inflammatory cells and induction of 
pro-inflammatory mediators.  
Better understanding of the immune dysfunction associated with aging will 
increase our ability to restore appropriate immune function and alleviate the burden of 
prostate cancer in the elderly. Future novel immunotherapies for prostate cancer could 
target the TH17/Treg imbalance associated with aging. Further investigation in this area 
is warranted.  
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Chapter 4: The Role of IL-17 and IL-6 in Aging related Prostate Tumorigenesis 
 4.1 Introduction  
Aging is positively correlated with increased circulating levels of many pro-
inflammatory cytokines such as interleukin-1 beta (IL-1β), tumor necrosis factors alpha 
(TNFα), interleukin-6 (IL-6) and interleukin-17 (IL-17) [83]. IL-6 is the most prominent 
cytokine shared across age-related pathologies having a strong chronic inflammatory 
component. There is strong evidence demonstrating that IL-6 serum concentration 
increases with age [46-49].  Maggio et al. reported that IL-6 mean values ranged from 
1.4 pg/ml (men) and 1.1 pg/ml (women) in the 65–74 years age group to 3.5 pg/ml 
(men) and 2.1 pg/ml (women) in persons 85 years and older, and that the age trend is 
partially independent of major confounders [48]. The etiology of chronically elevated IL-
6 in older adults is likely multifactorial, with increased presence of disease states, 
declines in estrogen and testosterone and changes on the immune system function and 
regulation, all contributing to IL-6 levels increase.  
In cancer, IL-6 is a growth/survival factor for a variety of tumor types. In prostate 
cancer, activation of STAT3 by IL-6 is correlated with increase proliferation, decreased 
apoptotic potential, regulation of epithelial-mesenchymal transition (EMT) and 
activation of androgen receptor genes [53].  A great number of reports have shown that 
elevated levels of circulating IL-6 are critical for prostate cancer development and 
progression [55, 56, 99, 100]. Human prostate cancer cell lines as well as clinical 
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prostate cancer specimens show constitutive expression of IL-6 and its receptor [101]. 
Studies have also demonstrated that IL-6 is elevated in sera of patients with castration 
resistant prostate cancer compared to normal controls, benign prostatic hyperplasia, 
and  localized prostate cancer [102]  
Tumorigenesis involves the acquisition of genetic and epigenetic changes that 
cause the aberrant loss or gain of functions by cellular proteins. The consequences 
include the ability of tumor cells to proliferate, resist apoptosis, demonstrate angiogenic 
potential, migrate, and invade, as well as the ability of these cells to evade immune 
surveillance. IL-6 can induce tumor initiation through activation of STAT3. Activated 
STAT3 has been linked to tumor initiation in part through the transcriptional regulation 
of critical target genes, including those for c-myc, c-fos, cyclin D1, matrix 
metalloproteinase 9 (MMP-9), MMP-2, vascular endothelial growth factor, Bcl-xL, Mcl-1, 
survivin, , as well as the epithelial-mesenchymal transition-related proteins – Snail, Slug   
and Twist [40, 103-105].  
Key features of early tumorigenesis include morphology changes, loss of cell 
contact inhibition and loss of cell polarity [106] . These early changes in cell morphology 
are widely associated with epithelial-mesenchymal transition (EMT), which also plays 
key roles in normal physiological processes such as embryogenesis, wound repair, and 
tissue remodeling [107-110]. The molecular hallmarks for EMT are down-regulation of 
epithelial markers, such as E-cadherin,, and up-regulation of mesenchymal markers  
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[109]. The induction of EMT can be triggered by transcription factors such as Snail, Slug, 
and Twist, which simultaneously repress the expression of genes that are required for 
the epithelial phenotype and induce the expression of genes required for mesenchymal 
properties [110]. The expression of these transcription factors is modulated by a 
number of signaling molecules, including STAT3 [111]. 
The objective of the following study was to better understand the connection 
between IL-6 and IL-17 in promoting prostate tumorigenesis. We previously 
demonstrated that IL-17 and IL-6 coming from aging T cells activate pro-inflammatory 
signaling in prostate epithelial cells, our next objective was to determine the role of IL-6 
and IL-17 in induction of age related prostate tumorigenesis. 
4.2 Materials and Methods  
4.2.1 Murine Models of an Aging Immune System 
C57BL/6 GPAT-1 +/- mice were obtained from Dr. Rosalind Coleman (University 
of North Carolina at Chapel Hill) and bred in our animal facilities to obtain homozygous 
knock-outs. Mice were fed a commercial chow diet (Prolab Rat/Mouse/Hamster 2000) 
provided by the animal facility. Offspring were numbered to monitor sex differences or 
differences between litters. Aged (>22 month old) C57BL/6 mice were purchased from 
the National Institute for Aging. Mice were housed on a 12:12-h light-dark cycle and had 
ad libitum access to food and water.   
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4.2.2 Cells and Cell Culture  
The LNCaP prostate cancer cell line was purchased from ATCC (Rockville, MD) 
and grown in RPMI-1640 containing 1% penicillin and streptomycin, supplemented with 
10% FBS in a 5% (v/v) CO2 humidified incubator at 37°C. The immortalized non-
transformed RWPE-1 prostate epithelial cell line was purchased from ATCC and grown in 
Keratinocyte Serum Free Medium (K-SFM) supplemented with bovine pituitary extract 
(BPE) and human recombinant epidermal growth factor (EGF) in a 5% (v/v) CO2 
humidified incubator at 37°C. The IL-17R shRNA clones (designated shIL-17R1 and shIL-
17R2) were generated by transfecting cells with the IL-17R shRNA Plasmid (h) sc-40037 
(Santa Cruz Biotechnologies, Santa Cruz, CA), using FuGENE HD transfection reagent 
(Roche, Basel, Switzerland) per manufacturer's instructions. Control LNCaP and RWPE-1 
cells (designated shControl) were generated by stably transfecting negative-control 
shRNA plasmids: Control Plasmid-B sc-108065 and Control Plasmid-C sc-108066 (Santa 
Cruz Biotechnologies, Santa Cruz, CA).  Puromycin antibiotic (Santa Cruz 
Biotechnologies, Santa Cruz, CA) was used to stably select transfected cells. All cells 
were maintained in selective RPMI-1640 or K-SFM media containing 4 µg/ml puromycin. 
RT-PCR was performed to monitor IL-17R gene expression knock-down using the IL-17R 
(h)-PR primer (Santa Cruz Biotechnologies, Santa Cruz, CA). In addition western blot 
analysis was used to confirm knock-down of the IL-17R gene. Antibodies against IL-17R 
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antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) and phospho- and total-STAT3 
(Cell Signaling) were used. 
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4.2.3 Wound Healing Assay 
Cells were seeded into 6-well flat-bottomed plates at a density of 5×105 cells per 
well and allowed to grow to 90% confluence. After aspirating the medium, the 
monolayer was scratched with a sterile 100 µl pipette tip to create a denuded zone 
(gap) of constant width. The scratched areas were photographed at 0, 12, 24 and 48  
hours after wounding using a phase-contrast microscopy. Cell migration was calculated 
as percentages of cell coverage to the initial cell-free zone. The values are the means of 
three independent experiments. 
4.2.4 Western blot analysis 
Prostate shIL-17R and shControl cells were exposed for 48 hours to sera or 
conditioned media from stimulated T-lymphocytes, then harvested and lysed in Laemmli 
lysis buffer for SDS-polyacrylamide gel electrophoresis. The lysates were probed with 
the following antibodies: pSTAT3, STAT3, E-cadherin, pSMAD2/3, VCAM, FAS, cAIP2 (all 
Cell Signaling, Boston, MA), cyclin D1 (Millipore, Billerica, MA), and cMYC, ICAM, 
Vimentin, Survivin and Actin (Santa Cruz Biotechnology, Santa Cruz, CA).  Luminescent 
signal was detected on a Syngene (Frederick, MD) imaging system and quantitative 
densitometric analysis measured using GeneTools. 
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4.2.5 RT-qPCR 
Prostate Cancer LNCaP cells were exposed to sera for 48 hours. Total RNA was isolated 
with the QIAGEN (Valencia, CA) RNA extraction system according to the manufacturer’s 
instructions and transcribed into complementary DNA (cDNA). Gene expression of 
Tenascin, Fibronectin and Intering β6 was measure using the respecting primers. 
Expression was quantified by QIAGEN SYBR green real-time PCR on an Eppendorf 
instrument (Santa Clara, CA). Nonspecific signals caused by primer dimers were 
excluded by dissociation curve analysis and use of non-template controls. To normalize 
for loaded cDNA, actin was used as an endogenous control.  
4.2.6 Statistics  
Values are presented as mean ± standard error of the mean (SEM).  For the 
Western blot analyses and Luciferase assays, means were compared across treatment 
groups using Student's t-test and one-way ANOVA Multiple Comparison was used for 
comparing more than two conditions. P≤0.05 was considered statistically significant 
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 4.3 Results  
4.3.1 IL-17 and IL-6 in the sera from old and aging mimic mice induce activation of 
STAT3 
Immunoblot analysis (Fig 4.1) confirmed that expression levels of phospho-
STAT3 and key STAT3 target genes were upregulated in LNCaP cells when exposed to 
AM and OLD versus WT mouse sera for 24 hours.  IL-17R knock-down in LNCaP cells 
decreased activation of STAT3 and expression of its gene targets following exposure to 
AM mouse sera. Knocking-down IL-17R in LNCaP cells does not modulate pSTAT3 
expression in LNCaP cells exposed to sera from OLD mice. However, IL-17R knock-down 
in LNCaP cells significantly decreased expression levels of pSTAT3 following exposure to 
OLD mouse sera plus IL-6 depleting antibody.  
Our results showed that expression levels of key STAT3 genes were also 
upregulated in RWPE-1 cells when exposed to OLD versus young WT mouse sera IL-17R 
knock-down in RWPE-1 cells decreased expression levels of pSTAT3 and its target genes 
following exposure to AM mouse sera (Fig 4.1). IL-17R knock-down in RWPE-1 cells did 
not decrease the expression levels of pSTAT3 after exposure to sera from OLD mice. 
However, when IL-6 was depleted from the sera from OLD mice, activation of STAT3 
diminished completely.  Overall these data suggests that IL-6 and IL-17 in the OLD and 
AM mice are essential for STAT3 activation in prostate epithelial cells.  
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WT         AM        OLD      IL6AB      WT        AM         OLD      IL6AB       WT         AM       OLD       IL6AB       
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pSTAT3
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shControl shIL17R1                              shIL17R2 
A                                                         LNCaP
 
Figure 4.1 Effects of IL-6 and IL-17 in the sera from OLD and AM mice on expression of 
key downstream targets of STAT3. 
Expression levels of pSTAT3, E-cadherin, ICAM-1, pSMAD2/3 and Vimetin LNCaP and 
RWPE cells expressing IL-17R shRNA (shIL-17R1 and shIL-17R2) or Control shRNA 
(shControl)  were detected by immunoblot after 24 hour exposure to sera from young 
wild-type (WT), old wild-type (OLD) or Aging Mimic (AM) mice or sera from old wild-type 
mice plus 10ug/ml IL-6 depleting antibody (O+IL6AB) (A). Graphs show the average 
relative densitometry values for three independent experiments. Different letters 
indicate statistically significant differences (p<0.05) (B). 
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4.3.2 Sera from old mice increase expression of the transcription factors Slug, Snail 
and Twist 
Transcription factors, such as Snail, Slug, and Twist, are pivotal activators of EMT 
[106]. Snail, Slug and Twist have been reported to mediate EMT, resulting in tumor 
progression, and poor survival in patients with prostate cancer. Several transcription 
factors have been reported to be involved in EMT via repression of E-cadherin, and 
some of these include Twist, Snail, and Slug [110, 112, 113].  Since Slug, Snail and Twist 
are important targets of STAT3 implicated in tumorigenesis , we focused our attention 
on these three proteins. 
After establishing that IL-6 and IL-17 in the sera from old and AM mice is 
important for activation of  STAT3 in prostate epithelial cells, we sought to determine 
whether this activation of STAT3 results in enhance expression of key regulators of 
prostate tumorigenesis.  We used qPCR to measure expression levels of Snail, Slug and 
Twist. Twist mRNA levels were upregulated in RWPE-1 non-transformed cells when 
exposed to OLD versus WT or AM mouse sera (Fig 4.2-4.3). Expression levels of Slug 
were upregulated in RWPE-1 non-transformed cells when exposed to OLD and AM 
versus WT sera. IL-17R knock-down in RWPE-1 cells significantly decreased expression of 
Twist (Fig 4.3) and Slug (Fig 4.2) following exposure to AM mouse sera. Knocking-down 
IL-17R in RWPE-1 cells moderately modulated expression of Slug (Fig 4.2) in RWPE-1 
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cells exposed to sera from OLD mice. However, IL-17R knock-down in RWPE-1 cells 
significantly decreased expression levels of Slug following exposure to OLD mouse sera 
plus IL-6 depleting antibody (Fig 4.2). 
Overall these data suggests that IL-6 and IL-17 in the sera from OLD and AM mice 
play important role on expression of proteins involved in tumor initiation.  
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Figure 4.2 Effects of IL-6 and IL-17 in the sera from OLD and AM mice on expression of 
Slug  
Slug mRNA levels in RWPE-1 cells expressing IL-17R shRNA (shIL-17R1 and shIL-17R2) or 
Control shRNA (shControl)  were detected by qPCR after exposure to sera from young 
wild-type (WT), old wild-type (OLD) or Aging Mimic (AM) or to sera from old wild-type 
mice plus 10ng/ml of IL-6 depleting antibody (OLD +IL6AB) (A). 
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Figure 4.3 Effects of IL-6 and IL-17 in the sera from OLD and AM mice on expression of 
Twist 
Twist mRNA levels in RWPE-1 cells expressing IL-17R shRNA (shIL-17R1 and shIL-17R2) or 
Control shRNA (shControl) were detected by qPCR after exposure to sera from young 
wild-type (WT), old wild-type (OLD) or Aging Mimic (AM) or to sera from old wild-type 
mice plus 10ng/ml of IL-6 depleting antibody (OLD +IL6AB) (A)  
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4.3.3 Prostate epithelial cell migration and invasion induced by sera from OLD and AM 
mice 
To determine whether the aging-associated induction of EMT could result in 
phenotypical changes in prostate epithelial cells, we assessed the impact of sera from 
OLD and AM mice on prostate epithelial cell migration (Fig 4.4) and prostate epithelial 
cell invasion (Fig 4.5). After 24 hour exposure to sera, we observed that sera from AM 
and OLD mice moderately increased migration of prostate epithelial cells. Furthermore, 
exposure to sera from AM mice increased prostate epithelial cell invasion by 1.8 fold 
(Fig 4.5).  A similar trend was seen when we examined the impact of exposure to OLD 
sera on prostate epithelial cell migration. OLD sera stimulated greater cell migration in 
comparison to WT sera. Overall, these preliminary results strongly suggest that aging-
associated circulating factors may promote early phenotypical chances related to 
prostate tumorigenesis. 
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Figure 4.4 Circulating Factors in the sera from AM and OLD mice promote migration of 
prostate epithelial cells 
Wound Healing  Assay was used to measure cell migration in response to sera from 
GPAT-1-/- Aging Mimic (AM), young wild-type (WT) or old wild-type (OLD) in LNCaP (A). 
Cells were exposed to sera for 24 hours and pictures were taken at   0, 12, 24 and 48 
hours after wounding. Bars represent cell coverage percentages.  
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Figure 4.5 Circulating Factors in the sera from AM mice promote invasion of prostate 
epithelial cells 
Cell invasion assay using 24- trans well plate was used to measure cell migration in 
response to sera from GPAT-1-/- Aging Mimic (AM) or young wild-type (WT) in LNCaP (A) 
cells. Presented is the average of three independent experiments standardized to WT. 
Different letters indicate significant differences (p<0.05). 
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4.4 Discussion 
One of the most significant risk factors for prostate cancer development is age 
[81]. One widely accepted explanation for the association between age and prostate 
cancer is the fact that prostate carcinogenesis is a characteristically long process [75] . 
Another possible mechanism responsible for prostate tumorigenesis in the elderly is 
aging-associated dysregulation of immune function. Aging is positively correlated with 
increased circulating levels of many pro-inflammatory cytokines such as interleukin-1 
beta (IL-1β), tumor necrosis factors alpha (TNFα), interleukin-6 (IL-6) and interleukin-17 
(IL-17) [83].  
Tumorigenesis involves the acquisition of genetic and epigenetic changes that 
cause the aberrant loss or gain of functions by cellular proteins. The consequences 
include the ability of tumor cells to proliferate, resist apoptosis, demonstrate angiogenic 
potential, migrate, and invade, as well as the ability of these cells to evade immune 
surveillance. IL-6 can induce tumor initiation through activation of STAT3. Activated 
STAT3 has been linked to tumor initiation in part through the transcriptional regulation 
of critical target genes involve in epithelial-mesenchymal transition [40, 103-105].  
Data presented in previous chapters demonstrated that IL-6 and IL-17 in the AM 
and OLD mice activate pro-inflammatory signaling in prostate epithelial cells that could 
lead to initiation of prostate tumorigenesis. In this chapter I presented data showing the 
influence of IL-6 and IL-17 on activating targets of STAT3 that induce aged related 
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tumorigenesis. The activation of STAT3 in combination with the previously observed 
activation of NF-κB could be crucial for mediation of tumor initiation in non-transformed 
prostate epithelial cells. Tumor initiation is a process in which normal cells acquire the 
first mutational hit that sends them on the tumorigenic track by providing growth and 
survival advantages over their neighbors [114, 115]. Various investigators have 
previously demonstrated that constitutively activation of STAT3 can transform 
immortalized fibroblasts and breast epithelial cells, in part as a consequence of 
increased cyclin D1 and MMP-9 expression [105]. However, the levels of neither of 
these targets were increased in non-transformed RWPE-1 cells expressing constitutively 
active STAT3 [104], suggesting that there are additional STAT3 targets which are 
important for tumor initiation rather than tumor progression.  
Azare et al. demonstrated that the introduction of an activating mutant form of 
STAT3 into non-tumorigenic RWPE-1 prostate epithelial cells resulted in tumorigenesis. 
Constitutively activated STAT3 decreased E-cadherin levels, increased numbers of 
lamellipodia and stress fibers, and enhanced migratory capacities, with an associated 
increase in the expression of EMT markers [104]. 
In the study described in this chapter we focused our attention on the role of IL-
6 and IL-17, in the sera from OLD and AM mice, in inducing expression of STAT3 and its 
key downstream targets. We specifically focused on Slug, Snail and Twist, given their 
known roles in early stages of tumorigenesis [116, 117]. We demonstrated that IL-6 and 
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IL-17 in the sera from OLD and AM mice are essential for activating STAT3 in prostate 
epithelial cells. Our results showed that STAT3 activation by circulating factors in the 
sera from OLD and AM mice led to significant increases in the expression of Slug and 
Twist. Our findings strongly suggested that IL-6 and IL-17 in the sera from AM and OLD 
mice induced EMT through up-regulation of Slug and Twist, thereby favoring prostate 
epithelial cell migration and invasion. Furthermore, our in vitro experiments showed 
that stimulation with sera from OLD and AM mice could markedly increase migratory 
and invasive ability of prostate epithelial cells. Transcription factors, such as Snail, Slug, 
and Twist, are pivotal activators of EMT [110]. Despite lack of direct evidence, our 
findings strongly suggested that IL-6 and IL-17 in the sera from OLD and AM induced 
EMT through up-regulation of Slug and Twist, thereby favoring prostate epithelial cell 
migration and invasion.  
In summary, the present study provides evidence that the aging-associated 
increase in circulating IL-6 and IL-17 promotes activation of STAT3 signaling in prostate 
epithelial cells.  Previously we demonstrated that T cells from our aging-mimic mice 
secrete elevated levels of IL-17, which in turn activate NF-κB. STAT3 and NF-κB have 
crucial and integrated roles in inflammatory responses that promote prostate cancer 
development and growth [111]. The elevated levels of circulating IL-6 and increased 
production of IL-17 during aging may be actively promoting prostate cancer 
development via activation of NF-κB and STAT3. Here we showed preliminary evidence 
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that demonstrates that circulating factors in the sera from AM and OLD mice induce 
EMT, prostate epithelial cell migration and invasion, possibly via activation of the NF-κB 
and STAT3 pathways. 
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Chapter 5:  Concluding Remarks 
5.1 Conclusions 
The population of the United States is getting older, due not only to aging 
boomers but also to an increase in life expectancy [118]. An aging population means 
increased diagnosis of prostate cancer. In a society where life expectancy has increased, 
it is important to determine how aging is related to prostate cancer risk. The goal of my 
thesis was to better understand the mechanism by which age-related changes of the 
immune system may contribute to increased susceptibility to prostate cancer. The aging 
process affects the adaptive cell-mediated immune response while causing a shift to a 
more inflammatory cytokine profile. I hypothesize that the age-related shift in T-
lymphocyte cytokine profile is a significant contributing factor to the association 
between age and prostate tumorigenesis. 
To test my hypothesis I used the GPAT-1-/- mice model of aging T cells. The GPAT- 
-/- mouse serves as a novel model of accelerated T-lymphocyte aging since its T-
lymphocytes possess multiple hallmarks of aging [28-31, 59]. The GPAT-1-/- mouse 
provides a unique opportunity to investigate the effects of aging T-lymphocytes and 
inflammation on prostate cancer development in the absence of other age-related 
complications. Our data first demonstrated that T-lymphocytes from the GPAT-1-/- 
mouse up-regulate the production and secretion of pro-inflammatory cytokines. Many 
of the pro-inflammatory cytokines produced by aged T-lymphocytes have been 
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implicated in the promotion of prostate tumorigenesis, primarily through the induction 
of other pro-inflammatory pathways and the activation of transcription factors like 
nuclear factor-kappa B (NF-κB). Analogous engagement of these pathways is 
recapitulated in the GPAT-1-/- mice model, strongly suggesting that the aged immune 
system plays a critical role in promoting prostate carcinogenesis. To further characterize 
and compare the relative cytokine expression profile from T-lymphocytes from young 
GPAT-1-/- mice to those derived from young and old (>22 month) wild-type (WT) mice, a 
cytokine immunoarray was used. Consistent with our previous observation, the 
inflammatory phenotype of GPAT-1-/- T-lymphocytes resembled that which is 
characteristic of aged murine T-lymphocytes (Fig 2.1). While the three groups had 
similar levels of several of the cytokines and chemokines (IL-1α and IL-1β, for example), 
the knock-out and old mice trended together for many others, including MIP1α and β, 
RANTES, IL-3 and I-309. Of note, compared to that found in the wild-type young mice, 
levels of IL-17 were 12- and 8-fold higher in the GPAT-1 -/- and old mice, respectively. 
Levels of IL-6 were more than ten times higher in the old mice compared to the GPAT-1-
/- and WT mice, suggesting that in old mice the presence of aged cells and tissue induce 
the further secretion of IL-6. 
Cytokines secreted by aging T-lymphocytes can induce pro-inflammatory 
signaling that promotes activation of the NF-κB pathway, which has previously been 
shown to be critical for prostate cancer progression [62-66, 77]. Therefore, to determine 
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how cytokines from the aged and aging-mimic GPAT-1-/- T-lymphocytes affect NF-κB 
transcriptional activity, non-transformed prostate epithelial cells and prostate cancer 
cells were exposed to sera from young WT, old WT or young GPAT-1-/-  aging mimic mice 
(AM) (Fig 2.2), as well as to conditioned media from young WT, old WT or GPAT-1-/- 
splenic T-lymphocytes (Fig 2.3). Circulating factors in the old WT and young GPAT-1-/- 
mouse sera both induced significantly greater NF-κB transcriptional activity in the PC-3 
and LNCaP prostate cancer cell lines (Fig 2.2A) in comparison to the young WT mouse 
sera, suggesting that the age-specific shift in T-lymphocyte function may be partly 
responsible for the increased NF-κB activity. Further, we observed a greater than 3-fold 
induction of NF-κB transcriptional activity in the non-transformed prostate epithelial 
cells (PrEC and RWPE-1) after exposure to young GPAT-1-/- mouse sera (Fig 2.2B), 
indicating that induction of NF-κB activity by the age-related elevation in circulating 
cytokines is not restricted to cancer cells.  This age-related NF-κB induction in the non-
transformed epithelial cells could play a role in their transformation to prostate cancer 
cells, suggesting one mechanistic link to explain why age is a risk factor for the 
development of prostate cancer. In addition, we observed that factors secreted 
specifically by GPAT-1-/- and old WT T-lymphocytes also induced NF-κB in the LNCaP 
prostate cancer cells, as well as in the non-transformed RWPE-1 cells, suggesting that 
the aged and GPAT-1-/- T-lymphocytes directly modulate NF-B activity in prostate 
epithelial and prostate cancer cells. 
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Since the initial data indicated that T-lymphocytes from GPAT-1 -/- secrete high 
levels of IL-17, a key cytokine known to promote carcinogenesis, and that transcription 
factors like NF-κB are critical for both inflammation and tumor growth, we sought to 
determine the role of IL-17 in GPAT-1-/--induced NF-κB activity (Fig 3.3). shRNA was used 
to knockdown the receptor for IL-17 (IL-17R) in  prostate cancer cells (LNCaP) and non-
transformed prostate epithelial cells (RWPE-1).  NF-κB activation was assessed in the IL-
17R shRNA clones exposed to sera from the experimental and control mice. In the 
absence of IL-17R, there was a significant reduction in NF-κB transcriptional activity 
induce by old WT and GPAT-1-/- mouse, in both LNCaP and RWPE-1 cells (Fig 3.3). This 
data indicates that the increased secretion of IL-17 from the GPAT-1-/- T-lymphocytes is 
playing a crucial role in the activation of pro-inflammatory signaling in prostate cancer 
and normal epithelial cells.  
Since our data demonstrated that sera from old mice has high levels of IL-6, an 
important cytokine that promotes pro-oncogenic inflammatory pathways. We sought to 
determine the role of age related IL-6 and IL-17 expression in inducing pro-tumorigenic 
mediators in prostate epithelial cells. Our results demonstrate that increased production 
of IL-6 and IL-17 in the old mice induce the STAT3 signaling pathway. (Fig 4.1) IL-17 
coming from aging T-cells, in combination with elevated IL-6 levels, induces pro-
inflammatory pathways that promote prostate tumor initiation and progression. The 
elevated levels of circulating IL-6 and increased production of IL-17 during aging may be 
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actively promoting prostate cancer development via activation of NF-κB and STAT3. 
Preliminary evidence demonstrates that circulating factors in the sera from AM and OLD 
mice induce EMT, prostate epithelial cell migration and invasion, possibly via activation 
of the NF-κB and STAT3 pathways. 
In summary, the results from this thesis indicate that aged T cells produce 
circulating factors that induce pro-inflammatory pathways such as NF-κB and STAT3, 
leading to induction of factors that promote EMT changes, proliferation and further 
inflammation. Furthermore, results from these studies suggest that the increased 
production of IL-17 by aged T-cells in combination with aged-related increase in IL-6 
secretion induces pro-inflammatory pathways in prostate cells that in turn contribute to 
a more malignant phenotype in the prostate. 
This study has important implications for our current understanding of the 
contribution of the immune system to prostate cancer development. The data 
presented in this dissertation strongly supports the concept that the aging immune 
system actively promotes cancer development and progression, possibly due to the 
induction of chronic inflammation in the microenvironment that results in upregulation 
of pathways leading to neoplastic changes. This contribution to the understanding of the 
role of the aging immune system in cancer development opens new avenues for 
development of potential preventive interventions as well as screening biomarkers. 
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5.2 Future Directions 
In our second chapter we  used a cytokine array to characterize and compare the 
relative cytokine expression profile from T-lymphocytes of young GPAT-1-/- (AM) mice to 
those derived from young and >22 month old (OLD) and wild-type (WT) mice. We 
demonstrated that the AM T-lymphocytes as well as the OLD T-lymphocytes secrete 
increased amount of pro-inflammatory cytokines, such as IL-17, IL-6, MIP-1 and I-309 
(Fig 2.1). On chapter three and four we focused our attention on the role that IL-17 and 
IL-6 play in inducing prostate tumorigenesis. For future studies it is important to study 
the impact of MIP-1 and I-309 in prostate tumorigenesis. 
 MIP1α and β levels are 20-fold and 10-fold higher in the sera from OLD mice 
versus WT mice. MIP-1 proteins are major factors produced by macrophages after 
stimulation from bacterial infection. They are crucial for immune responses towards 
infection and inflammation. MIP-1 proteins also induce the synthesis and release of 
other pro-inflammatory cytokines such as interleukin 1 (IL-1), IL-6 and TNF-α from 
fibroblasts and macrophages [119]. Since these proteins are potent inducers of 
inflammation and they are highly elevated in AM and OLD mice, it is important for 
future studies to examine the role of MIPα and β in prostate cancer development. 
Knocking-down the receptor for IL-17R strongly diminished the activation of NF-κB and 
STAT3 by sera from OLD and AM mice, suggesting that IL-17 in the sera is mainly 
responsible for activating these pro-inflammatory pathways in prostate epithelial cells. 
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It is important to understand why MIP-1 is not playing such an important role in 
activating NF-κB in prostate epithelial cells.  It is also interesting to notice that I-309 
expression levels are 16- and 11 fold higher in the OLD and AM mice compared to the 
WT mice. I-309 is secreted by activated T cells and attracts monocytes, NK cells, and 
immature B cells. Since elevated amounts of I-309 in the sera from AM and OLD mice 
may further increase inflammation, it is important to investigate to role of I-309 in 
prostate cancer initiation and progression. 
For future studies is also imperative to understand the interaction between 
aging prostate epithelial cells and aging T cells. In order to understand the interaction 
between aging prostate epithelial cells and aging T cells in the prostate 
microenvironment, we first sought to determine the type of T cells that were infiltrating 
the prostate from AM and OLD mice. Preliminary results indicate that there are more 
TH17 T cells in the prostate from AM and OLD mice versus the WT mice (Appendix 1).  
We also did a series of preliminary in-vitro studies where we exposed T cells 
from human to conditioned media from senescent prostate epithelial and fibroblast 
cells and measured cytokine expression on the T cells. For these studies we used Jurkat 
T cells.  Jurkat cells are an immortalized line of human T cells that are used to study 
acute T cell signaling. Jurkat cells are also useful for T cell signaling studies because of 
their ability to produce interleukin 2. Our preliminary studies demonstrated that 
conditioned media from senescent prostate epithelial cells was able to regulate Jurkat T 
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cell IL-2 expression (Appendix 2). Suggesting that aged prostate cells can potentially 
affect the phenotype of T cells in the prostate microenvironment. 
We also studied the potential effect of condition media from aging T cells on 
recruitment of inflammatory cells to the prostate. Our results demonstrated that 
conditioned media from aging T cells induce monocyte recruitment to the prostate 
(Appendix 3). This data indicates that the enhanced cross-talk between the immune 
cells and the epithelial cells in an aging environment can mediate tumor-promoting 
inflammation. Additional studies need to be done to further characterize the interaction 
between aging prostate epithelial cells and the aging immune system.  
It is also important to further understand the mechanism by which aged T cells 
become dysregulated. Better understanding of the mechanisms by which the immune 
system deteriorates and contributes to prostate cancer development may lead to better 
interventions in the elderly. 
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Appendix 1:  AM and OLD mice have PIN lesions and increased levels of prostate-
infiltrating TH17 cells 
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Figure 5.1 T-cell aging mimic mice have PIN lesions and increased levels of prostate-
infiltrating TH17 cells.   
(A -C) CD4+ Immunohistochemistry staining of prostate tissue from AM, WT and OLD 
mice. (D-F) RORyt (TH17 marker) immunohistochemistry staining of prostate tissue from 
AM, WT and OLD mice. (G-I) T-bet (TH1 marker) immunohistochemistry staining of 
prostate tissue from AM, WT and OLD mice. Bar graph shows number of CD4+, TH1 
(Tbet) and TH17 (RORyt) T cells per 10x field. Pie graph shows the proportion of TH1 
versus TH17 cells in AM mice versus WT mice. 
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Appendix 2: Conditioned Media from Senescent Epithelial Cells Decreases T cell IL-2 
production 
 
Figure 5.2 IL-2 expression in human Jurkat T cells 
IL-2 mRNA levels in stimulated and unstimulated Jurkat T cells were detected by qPCR 
after exposure to conditioned media from senescent and wild-type prostate epithelial 
RWPE-1 cells. IL-2 expression levels were 2.5-fold lower in the stimulated Jurkat T cells 
exposed to conditioned media from senescent RWPE-1 cells versus cells exposed to 
conditioned media from wild-type RWPE-1 cells 
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Appendix 3: LNCaP cells treated with Conditioned Media from GPAT-1-/- T cells 
moderately induce recruitment of monocytes 
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Figure 5.3 LNCaP cells treated with Conditioned Media from GPAT-1-/- T cells 
moderately induce recruitment of monocytes. 
 
To determine if circulating factors coming from aging T-cells induce the production 
of specific proteins that recruit monocytes to the prostate, we prepared conditioned 
media by exposing LNCaP prostate cancer cells to sera from AM mice and preformed an 
invasion assay to see if agents released in the conditioned media attract monocytes to 
prostate cancer cells. The conditioned media from LNCaP cells exposed to sera from the 
GPAT-1 KO mice induced monocyte invasion by 37% as compared to control (WT). 
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